<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Vaccines (Basel)</journal-id><journal-id journal-id-type="iso-abbrev">Vaccines (Basel)</journal-id><journal-id journal-id-type="publisher-id">vaccines</journal-id><journal-title-group><journal-title>Vaccines</journal-title></journal-title-group><issn pub-type="epub">2076-393X</issn><publisher><publisher-name>MDPI</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40006739</article-id><article-id pub-id-type="pmc">PMC11860339</article-id><article-id pub-id-type="doi">10.3390/vaccines13020193</article-id><article-id pub-id-type="publisher-id">vaccines-13-00193</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Innate Sensing of Viral Nucleic Acids and Their Use in Antiviral Vaccine Development</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Enya</surname><given-names>Takuji</given-names></name></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid" authenticated="true">https://orcid.org/0000-0002-3094-3769</contrib-id><name><surname>Ross</surname><given-names>Susan R.</given-names></name><xref rid="c1-vaccines-13-00193" ref-type="corresp">*</xref></contrib></contrib-group><contrib-group><contrib contrib-type="editor"><name><surname>Von Laer</surname><given-names>Dorothee</given-names></name><role>Academic Editor</role></contrib><contrib contrib-type="editor"><name><surname>De la Torre</surname><given-names>Juan</given-names></name><role>Academic Editor</role></contrib></contrib-group><aff id="af1-vaccines-13-00193">Department of Microbiology and Immunology, University of Illinois at Chicago College of Medicine, Chicago, IL 60612, USA; <email>enya0129@uic.edu</email></aff><author-notes><corresp id="c1-vaccines-13-00193"><label>*</label>Correspondence: <email>srross@uic.edu</email>; Tel.: +1-(312)-996-4945</corresp></author-notes><pub-date pub-type="epub"><day>16</day><month>2</month><year>2025</year></pub-date><pub-date pub-type="collection"><month>2</month><year>2025</year></pub-date><volume>13</volume><issue>2</issue><elocation-id>193</elocation-id><history><date date-type="received"><day>09</day><month>12</month><year>2024</year></date><date date-type="rev-recd"><day>23</day><month>1</month><year>2025</year></date><date date-type="accepted"><day>11</day><month>2</month><year>2025</year></date></history><permissions><copyright-statement>&#x000a9; 2025 by the authors.</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</ext-link>).</license-p></license></permissions><abstract><p>Viruses pose a significant threat to humans by causing numerous infectious and potentially fatal diseases. Understanding how the host&#x02019;s innate immune system recognizes viruses is essential to understanding pathogenesis and ways to control viral infection. Innate immunity also plays a critical role in shaping adaptive immune responses induced by vaccines. Recently developed adjuvants often include nucleic acids that stimulate pattern recognition receptors which are essential components of innate immunity necessary for activating antigen-presentation cells and thereby bridging innate and adaptive immunity. Therefore, understanding viral nucleic acid sensing by cytosolic sensors is essential, as it provides the potential means for developing new vaccine strategies, including effective adjuvants.</p></abstract><kwd-group><kwd>innate immune system</kwd><kwd>cytosolic sensors</kwd><kwd>vaccine</kwd><kwd>pattern recognition receptors</kwd><kwd>adjuvant</kwd><kwd>mRNA cap structure</kwd></kwd-group><funding-group><award-group><funding-source>NIH/NIAID</funding-source><award-id>1R01AI174538</award-id></award-group><funding-statement>This research was funded by NIH/NIAID 1R01AI174538.</funding-statement></funding-group></article-meta></front><body><sec sec-type="intro" id="sec1-vaccines-13-00193"><title>1. Introduction</title><p>During virus infection, viral nucleic acids that are both released from virions during capsid disintegration and generated upon replication in host cells are recognized by specific receptors termed pattern recognition receptors (PRRs). PRRS play a critical role in detecting viral nucleic acids and, when activated, induce the production of type I interferons (IFNs) and cytokines, resulting in the expression of IFN-stimulated genes (ISGs) in sentinel cells such as monocytes and dendritic cells [<xref rid="B1-vaccines-13-00193" ref-type="bibr">1</xref>]. This early immune activation subsequently facilitates adaptive immune responses, including antigen trafficking to the lymphoid organs, antigen presentation, and the activation of T and B lymphocytes. The process is fundamental to the generation of virus-specific immunological memory, enhancing long-term protection against future infections.</p><p>Live attenuated and inactivated virus vaccines contain many of the same nucleic acid and protein molecules as replication-competent viruses and thus also have the potential to trigger innate immune responses and contribute to adaptive immunity. Moreover, the recently developed mRNA vaccines leverage PRR recognition mechanisms to induce effective immune responses [<xref rid="B2-vaccines-13-00193" ref-type="bibr">2</xref>]. These vaccines introduce RNA encoding viral proteins into host cells, where PRR recognition leads to IFN-I and cytokine production along with the biosynthesis of viral antigens [<xref rid="B3-vaccines-13-00193" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00193" ref-type="bibr">4</xref>,<xref rid="B5-vaccines-13-00193" ref-type="bibr">5</xref>,<xref rid="B6-vaccines-13-00193" ref-type="bibr">6</xref>]. This unique feature of mRNA vaccines&#x02014;their ability to simultaneously activate both innate and adaptive immune responses&#x02014;is a key factor in their rapid and effective induction of protective immunity.</p><p>Currently, attention is directed towards adjuvants that enhance PRR activation, facilitating robust immune responses upon vaccination [<xref rid="B7-vaccines-13-00193" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00193" ref-type="bibr">8</xref>]. This strategy offers the potential for more rapid and potent immune protection against viral pathogens. Thus, understanding the cellular recognition of viral nucleic acids and the subsequent signal transduction is essential for improving the design and efficacy of antiviral vaccines. Several excellent reviews that cover PRR recognition of pathogen molecules other than nucleic acids have recently been published [<xref rid="B7-vaccines-13-00193" ref-type="bibr">7</xref>,<xref rid="B8-vaccines-13-00193" ref-type="bibr">8</xref>]. In this review, we present a brief overview of the factors involved in recognizing viral nucleic acids and their signaling pathways and describe recent advances in the use of such antiviral responses in vaccine development.</p></sec><sec id="sec2-vaccines-13-00193"><title>2. The Role of Nucleic Acid Sensing in Pathogen Recognition and Immune Response</title><p>The innate immune system serves as a first line of defense against pathogenic infections by employing an array of PRRs and associated signaling pathways that detect the pathogen-associated molecular patterns (PAMPs) found in the various nucleic acids generated during virus infection, including single-stranded RNA (ssRNA), single-stranded DNA (ssDNA), RNA&#x02013;DNA hybrids, double-stranded RNA (dsRNA), and double-stranded DNA (dsDNA). These PRRs, which include Toll-like receptors (TLRs), NOD-like receptors (NLRs), the retinoic acid-inducible gene I-like receptors (RLRs) retinoic acid-inducible gene-I (RIG-I) and melanoma differentiation-associated protein-5 (MDA5), absent in melanoma 2 (AIM2)-like receptors (ALRs), cyclic GMP&#x02013;AMP synthase (cGAS), and receptors with DEAD box helicase (DDX) and zinc finger (ZNF) domains, are evolutionarily conserved and play an essential role in mounting a rapid innate immune response [<xref rid="B1-vaccines-13-00193" ref-type="bibr">1</xref>,<xref rid="B9-vaccines-13-00193" ref-type="bibr">9</xref>,<xref rid="B10-vaccines-13-00193" ref-type="bibr">10</xref>,<xref rid="B11-vaccines-13-00193" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00193" ref-type="bibr">12</xref>,<xref rid="B13-vaccines-13-00193" ref-type="bibr">13</xref>] (<xref rid="vaccines-13-00193-f001" ref-type="fig">Figure 1</xref>).</p><p>Once PAMPs are recognized, PRR signaling initiates the production of IFNs, pro-inflammatory cytokines, and chemokines, which in turn activate transcription of additional antiviral genes. For example, type I IFNs (IFN-I) bind to the IFN &#x003b1;/&#x003b2; receptor (IFNAR), which activates Janus kinases (JAKs). JAKs then phosphorylate and activate the transcription factors signal transducer and activator of transcription 1 (STAT1) and STAT2, leading to the expression of IFN-stimulated genes (ISGs) [<xref rid="B14-vaccines-13-00193" ref-type="bibr">14</xref>,<xref rid="B15-vaccines-13-00193" ref-type="bibr">15</xref>,<xref rid="B16-vaccines-13-00193" ref-type="bibr">16</xref>] (<xref rid="vaccines-13-00193-f001" ref-type="fig">Figure 1</xref>).</p><p>Pathogens infect different cell types and tissues, and many replicate in distinct cellular compartments. This, and the need for targeted responses to different pathogens, has likely led to the expansion of PRRs with different signaling pathways. These specific sensing and signaling pathways are also important targets for virus proteins that counteract their action and cause host immune evasion [<xref rid="B1-vaccines-13-00193" ref-type="bibr">1</xref>,<xref rid="B17-vaccines-13-00193" ref-type="bibr">17</xref>]. As a result, this greatly accelerates host&#x02013;pathogen co-evolution [<xref rid="B18-vaccines-13-00193" ref-type="bibr">18</xref>,<xref rid="B19-vaccines-13-00193" ref-type="bibr">19</xref>,<xref rid="B20-vaccines-13-00193" ref-type="bibr">20</xref>,<xref rid="B21-vaccines-13-00193" ref-type="bibr">21</xref>].</p></sec><sec id="sec3-vaccines-13-00193"><title>3. TLRs in Innate Immunity: Detecting Pathogens and Triggering Immune Signaling Pathways</title><p>TLRs are a conserved family of type I transmembrane proteins that play crucial roles in innate immunity by recognizing a variety of PAMPs, thereby initiating immune responses against a broad spectrum of pathogens [<xref rid="B9-vaccines-13-00193" ref-type="bibr">9</xref>,<xref rid="B13-vaccines-13-00193" ref-type="bibr">13</xref>]. TLRs are strategically located either on the cell surface or within intracellular compartments such as endosomes and lysosomes. For example, TLR1, 2, 4, 5, 6, and 11 are primarily responsible for recognizing extracellular microbial components, while TLR3, 7, 8, and 9 recognize viral or bacterial nucleic acids within endosomal compartments. Upon ligand binding, TLRs undergo dimerization, forming either homodimers or heterodimers, which then trigger intracellular signaling cascades through their Toll/IL-1 receptor (TIR) domain. This interaction recruits specific adaptor proteins, activating downstream pathways such as the NF-&#x003ba;B signaling axis or the TBK1 pathway. These cascades culminate in the activation of transcription factors, including NF-&#x003ba;B, IRF3 and 7, driving the production of pro-inflammatory cytokines and IFN-I essential for mounting effective immune responses.</p><p>TLRs act as PRRs for a wide variety of PAMPs. TLR2 forms heterodimers with either TLR1 or TLR6, recognizing structurally diverse bacterial lipoproteins. TLR4, while primarily recognizing LPS from Gram-negative bacteria, also detects components from certain parasites and fungi, as well as proteins derived from viruses and host cells (see below) [<xref rid="B9-vaccines-13-00193" ref-type="bibr">9</xref>,<xref rid="B13-vaccines-13-00193" ref-type="bibr">13</xref>,<xref rid="B22-vaccines-13-00193" ref-type="bibr">22</xref>]. TLR5 binds to flagellin, a protein found in bacterial flagella, and TLR11 is known to recognize profilin-like proteins derived from protozoa [<xref rid="B9-vaccines-13-00193" ref-type="bibr">9</xref>,<xref rid="B13-vaccines-13-00193" ref-type="bibr">13</xref>,<xref rid="B23-vaccines-13-00193" ref-type="bibr">23</xref>]. TLR2 also interacts with viral proteins as a TLR2/6 heterodimer, mediating cytokine production during infection with some strains of lymphocytic choriomeningitis virus (LCMV), New World arenaviruses, measles virus, respiratory syncytial virus, and herpes simplex virus (HSV)-1 [<xref rid="B24-vaccines-13-00193" ref-type="bibr">24</xref>,<xref rid="B25-vaccines-13-00193" ref-type="bibr">25</xref>,<xref rid="B26-vaccines-13-00193" ref-type="bibr">26</xref>,<xref rid="B27-vaccines-13-00193" ref-type="bibr">27</xref>,<xref rid="B28-vaccines-13-00193" ref-type="bibr">28</xref>].</p><p>TLRs 3, 7, and 9 are important sensors of viral nucleic acids. TLR3 recognizes dsRNA, triggering immune responses in response to West Nile virus (WNV) and influenza A virus (IAV), as well as HSV [<xref rid="B29-vaccines-13-00193" ref-type="bibr">29</xref>,<xref rid="B30-vaccines-13-00193" ref-type="bibr">30</xref>,<xref rid="B31-vaccines-13-00193" ref-type="bibr">31</xref>,<xref rid="B32-vaccines-13-00193" ref-type="bibr">32</xref>,<xref rid="B33-vaccines-13-00193" ref-type="bibr">33</xref>]. TLR7 detects viral ssRNA, inducing the production of type I interferons and inflammatory cytokines during infections with IAV, vesicular stomatitis virus, and WNV, as well as in response to human immunodeficiency virus (HIV)-1 ssRNA transfection [<xref rid="B34-vaccines-13-00193" ref-type="bibr">34</xref>,<xref rid="B35-vaccines-13-00193" ref-type="bibr">35</xref>,<xref rid="B36-vaccines-13-00193" ref-type="bibr">36</xref>,<xref rid="B37-vaccines-13-00193" ref-type="bibr">37</xref>]. TLR9, the first identified DNA sensor, recognizes unmethylated CpG DNA as its ligand, participating in immune responses to bacterial and viral DNA, and plays a crucial role in inducing interferon and cytokine production during infections with HSV, adenovirus, and poxvirus [<xref rid="B38-vaccines-13-00193" ref-type="bibr">38</xref>,<xref rid="B39-vaccines-13-00193" ref-type="bibr">39</xref>,<xref rid="B40-vaccines-13-00193" ref-type="bibr">40</xref>].</p></sec><sec id="sec4-vaccines-13-00193"><title>4. NOD-like Receptors</title><p>The NLR family is classified into four subfamilies (NLRA, NLRB, NLRC, and NLRP) based on the structure of their N-terminal effector domains. NLRs are expressed in the cytoplasm of immune cells such as macrophages and dendritic cells, as well as in non-immune cells, including epithelial cells, and play a crucial role in detecting molecules associated with intracellular infections [<xref rid="B41-vaccines-13-00193" ref-type="bibr">41</xref>,<xref rid="B42-vaccines-13-00193" ref-type="bibr">42</xref>]. NLRs recognize PAMPs such as those found in bacterial cell walls and danger-associated molecular patterns (DAMPs) released from injured cells [<xref rid="B43-vaccines-13-00193" ref-type="bibr">43</xref>]. The activation of these NLRs forms an inflammasome complex, which stimulates pro-interleukin-1&#x003b2; (IL-1&#x003b2;) and IL-18 production, triggering an immune response and contributing to host defense against pathogens [<xref rid="B44-vaccines-13-00193" ref-type="bibr">44</xref>].</p><p>NOD2 and NLRP9b in particular are thought to serve as viral nucleic acid sensors. NOD2 plays a key role in recognizing both bacterial-derived muramyl dipeptide motifs and virus-derived ssRNA, and subsequently activates downstream signaling pathways, including NF-&#x003ba;B and MAPK, leading to the induction of IFN-I [<xref rid="B41-vaccines-13-00193" ref-type="bibr">41</xref>,<xref rid="B45-vaccines-13-00193" ref-type="bibr">45</xref>,<xref rid="B46-vaccines-13-00193" ref-type="bibr">46</xref>,<xref rid="B47-vaccines-13-00193" ref-type="bibr">47</xref>]. NLRP9b recognizes viral dsRNA through the RNA helicase DHX9 and forms an inflammasome that inhibits rotavirus replication in intestinal cells [<xref rid="B48-vaccines-13-00193" ref-type="bibr">48</xref>].</p></sec><sec id="sec5-vaccines-13-00193"><title>5. RLRs, cGAS, ALRs, and DDX Molecules in the Antiviral Response</title><p>RLRs are the main sensors of infection by RNA viruses such as paramyxoviruses, flaviviruses, orthomyxoviruses, and coronaviruses, among others. These cytosolic sensors, which include RIG-I and MDA5, distinguish between self- and non-self-mRNAs by recognizing the PAMPs dsRNA with a 5&#x02032; di- or triphosphate or long dsRNA, respectively [<xref rid="B49-vaccines-13-00193" ref-type="bibr">49</xref>,<xref rid="B50-vaccines-13-00193" ref-type="bibr">50</xref>]. They then oligomerize and interact with a downstream scaffold protein associated with the mitochondrial membrane, Mitochondrial antiviral-signaling protein (MAVS), which initiates signaling via TRAF and the IKK family of proteins, resulting in the activation of IRF3, IRF7, and NF-kB. Another member of the RLR family, LGP2, also binds viral RNA but not MAVS and modulates RIG-I and MDA5 activity.</p><p>Retroviruses generate PAMPs at distinct stages of the replication cycle, which are recognized by different PRRs to orchestrate an effective antiviral response [<xref rid="B51-vaccines-13-00193" ref-type="bibr">51</xref>,<xref rid="B52-vaccines-13-00193" ref-type="bibr">52</xref>,<xref rid="B53-vaccines-13-00193" ref-type="bibr">53</xref>]. During retrovirus replication, host cells are exposed to various forms of nucleic acid, such as ssRNA, ssDNA, RNA&#x02013;DNA hybrids, dsRNA, and dsDNA. These nucleic acids can be detected in the cytoplasm, and in some cases, within the nucleus when immature viral particles are internalized and degraded by host cells [<xref rid="B54-vaccines-13-00193" ref-type="bibr">54</xref>]. Consequently, multiple PRRs including TLRs, DDXs, ALRs, and cGAS are activated to initiate the host immune response. Furthermore, retroviral virions and proteins are recognized by PRRs [<xref rid="B55-vaccines-13-00193" ref-type="bibr">55</xref>]. It has also been suggested that lenti- and retroviruses incorporate the lipopolysaccharide (LPS)-binding protein CD14 into their membranes, which enables them to activate TLR4, the LPS PRR found on the cell surface [<xref rid="B56-vaccines-13-00193" ref-type="bibr">56</xref>,<xref rid="B57-vaccines-13-00193" ref-type="bibr">57</xref>].</p><p>cGAS is responsible for the innate immune response to cytosolic and nuclear DNA released from DNA viruses and retroviruses upon infection or produced in actively infected cells [<xref rid="B58-vaccines-13-00193" ref-type="bibr">58</xref>,<xref rid="B59-vaccines-13-00193" ref-type="bibr">59</xref>,<xref rid="B60-vaccines-13-00193" ref-type="bibr">60</xref>,<xref rid="B61-vaccines-13-00193" ref-type="bibr">61</xref>]. In response to binding DNA, cGAS synthesizes cyclic guanosine monophosphate&#x02013;adenosine monophosphate (cGAMP) [<xref rid="B58-vaccines-13-00193" ref-type="bibr">58</xref>]. cGAMP is also produced when mitochondrial DNA released upon damage induced by RNA viruses such as influenza and flaviviruses binds to cGAS [<xref rid="B62-vaccines-13-00193" ref-type="bibr">62</xref>,<xref rid="B63-vaccines-13-00193" ref-type="bibr">63</xref>]. cGAMP binds to Stimulator of interferon genes (STING) on the endoplasmic reticulum (ER), triggering its activation and subsequent dimerization. Thereafter, STING associates with TANK-binding kinase 1 (TBK1) and translocates to the Golgi apparatus. TBK1 phosphorylates interferon regulatory factor (IRF) 3 and NF-&#x003ba;B, which then move to the nucleus, leading to the production of IFN-I and pro-inflammatory cytokines [<xref rid="B64-vaccines-13-00193" ref-type="bibr">64</xref>].</p><p>ALRs are a family of proteins with evidence of pathogen-driven strong positive selection that have important roles in innate immune signaling pathways [<xref rid="B12-vaccines-13-00193" ref-type="bibr">12</xref>,<xref rid="B18-vaccines-13-00193" ref-type="bibr">18</xref>,<xref rid="B20-vaccines-13-00193" ref-type="bibr">20</xref>,<xref rid="B65-vaccines-13-00193" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00193" ref-type="bibr">66</xref>]. ALRs consist of an N-terminal pyrin domain (PYD), which facilitates homotypic and heterotypic interactions with PYD-containing and other proteins, and a C-terminal hematopoietic expression, interferon-inducible nature, and nuclear localization (HIN) domain, which binds DNA [<xref rid="B12-vaccines-13-00193" ref-type="bibr">12</xref>,<xref rid="B18-vaccines-13-00193" ref-type="bibr">18</xref>]. <italic toggle="yes">ALR</italic> genes, which are encoded at a single locus in mammals, are under strong selection, and the copy number of these genes varies between species [<xref rid="B18-vaccines-13-00193" ref-type="bibr">18</xref>,<xref rid="B65-vaccines-13-00193" ref-type="bibr">65</xref>]. For example, in contrast to the 5 <italic toggle="yes">ALR</italic> genes found in humans, there are 13&#x02013;16 mouse <italic toggle="yes">Alrs</italic>, depending on the inbred mouse strain, encoded at a single locus on mouse chromosome 1 [<xref rid="B18-vaccines-13-00193" ref-type="bibr">18</xref>,<xref rid="B65-vaccines-13-00193" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00193" ref-type="bibr">66</xref>,<xref rid="B67-vaccines-13-00193" ref-type="bibr">67</xref>].</p><p>AIM2 exhibits distinct characteristics from other ALRs and is classified into a separate clade in phylogenetic analyses; upon binding DNA, it activates the inflammasome pathway [<xref rid="B12-vaccines-13-00193" ref-type="bibr">12</xref>,<xref rid="B18-vaccines-13-00193" ref-type="bibr">18</xref>,<xref rid="B65-vaccines-13-00193" ref-type="bibr">65</xref>]. AIM2 is conserved across species in contrast to the other ALRs, which exhibit greater similarity to one another within the same species than across different species. The unique PYD and HIN domains of AIM2 compared to the domains found in other ALRs supports its different function [<xref rid="B18-vaccines-13-00193" ref-type="bibr">18</xref>,<xref rid="B65-vaccines-13-00193" ref-type="bibr">65</xref>]. Indeed, the HIN domains of the other ALRs, including IFI16 in humans and IFI203 and IFI204 in mice, bind DNA and induce IFN-I signaling in response to pathogens rather than inflammation [<xref rid="B68-vaccines-13-00193" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-13-00193" ref-type="bibr">69</xref>,<xref rid="B70-vaccines-13-00193" ref-type="bibr">70</xref>,<xref rid="B71-vaccines-13-00193" ref-type="bibr">71</xref>,<xref rid="B72-vaccines-13-00193" ref-type="bibr">72</xref>].</p><p>IFI16 binds stem-rich ssDNA and viral dsDNA via its HIN-B domain to induce IFN-I responses but fails to induce IFN responses to RNA&#x02013;DNA hybrids [<xref rid="B69-vaccines-13-00193" ref-type="bibr">69</xref>,<xref rid="B73-vaccines-13-00193" ref-type="bibr">73</xref>]. In addition to nucleic acid structures, it has been shown that nucleic acid length can influence the magnitude of the IFN-I response mediated by IFI16 [<xref rid="B69-vaccines-13-00193" ref-type="bibr">69</xref>]. This, combined with the fact that depletion of IFI16 leads to increased lentiviral replication, suggests that IFI16 has higher affinities for certain nucleic acid forms generated during viral infection [<xref rid="B73-vaccines-13-00193" ref-type="bibr">73</xref>]. Similarly, both cGAS and IFI16 are required for IRF-3 signaling in HIV-infected cells; cGAS especially plays a crucial role in the detection of HIV reverse transcription products and the dimerization of IRF-3 [<xref rid="B74-vaccines-13-00193" ref-type="bibr">74</xref>]. The murine ALR, IFI203, requires its HIN domain to bind early murine leukemia virus (MLV) reverse transcripts and strong stop ssDNA, and participates in the IFN-I response to MLV infection [<xref rid="B68-vaccines-13-00193" ref-type="bibr">68</xref>]. These studies demonstrate that different sequences, lengths, and secondary structures of pathogen nucleic acids might play a role in ALR pathogen recognition and the induction of innate immune responses.</p><p>In addition, IFI16 plays critical roles in the nucleus by orchestrating both innate immune sensing and epigenetic regulation of HSV DNA. IFI16, in cooperation with cGAS, detects HSV DNA as foreign, triggering innate immune signaling pathways that activate antiviral defense mechanisms. Additionally, IFI16 promotes the heterochromatinization of HSV DNA, leading to the epigenetic silencing of viral genes, thereby limiting viral replication. This function underscores IFI16&#x02019;s role in integrating epigenetic regulation with innate immune responses, highlighting its importance as a nuclear defense mechanism that restricts HSV replication and enhances host immunity [<xref rid="B75-vaccines-13-00193" ref-type="bibr">75</xref>].</p><p>Paramyxoviruses may also activate the innate immune system via interaction with ALRs. Following infection with Nipah virus and measles virus, both cGAS and IFI16 activate STING, leading to the production of IFN&#x003b2; [<xref rid="B76-vaccines-13-00193" ref-type="bibr">76</xref>]. Additionally, syncytium formation by paramyxoviruses results in the leakage of mitochondrial DNA into the cytoplasm, which is subsequently detected by cGAS and IFI16 [<xref rid="B76-vaccines-13-00193" ref-type="bibr">76</xref>].</p><p>A number of DEAD-box helicases in addition to the RLR family have been implicated in virus sensing. DDX3 recognizes short, abortive RNA transcripts produced in HIV-infected cells [<xref rid="B77-vaccines-13-00193" ref-type="bibr">77</xref>]. DDX41 has been implicated in the recognition of retroviral nucleic acids and may directly interact with STING following nucleic acid detection [<xref rid="B65-vaccines-13-00193" ref-type="bibr">65</xref>,<xref rid="B66-vaccines-13-00193" ref-type="bibr">66</xref>,<xref rid="B68-vaccines-13-00193" ref-type="bibr">68</xref>,<xref rid="B69-vaccines-13-00193" ref-type="bibr">69</xref>,<xref rid="B78-vaccines-13-00193" ref-type="bibr">78</xref>]. DDX41 is also a critical sensor of viruses in fish [<xref rid="B79-vaccines-13-00193" ref-type="bibr">79</xref>]. Like cGAS and several ALRs, nucleic acid sensing by DDX41 plays a crucial role in the activation of STING-dependent IFN induction, as well as the formation of inflammasomes and the initiation of inflammatory cell death [<xref rid="B11-vaccines-13-00193" ref-type="bibr">11</xref>,<xref rid="B12-vaccines-13-00193" ref-type="bibr">12</xref>]. Our group demonstrated that DDX41 detects the RNA&#x02013;DNA hybrids generated during the first steps of MLV reverse transcription. Dendritic cells, but not myeloid-derived cells, were found to be primarily responsible for the in vivo control of viral infection by effectively initiating DDX41-mediated antiviral immune responses. DDX41 also recognizes RNA&#x02013;DNA hybrids released from damaged mitochondria during influenza virus infection [<xref rid="B62-vaccines-13-00193" ref-type="bibr">62</xref>]. These findings suggest that DDX41 and cGAS recognize RNA hybrids and dsDNA produced at the early and later stages of reverse transcription, respectively [<xref rid="B78-vaccines-13-00193" ref-type="bibr">78</xref>].</p></sec><sec id="sec6-vaccines-13-00193"><title>6. The STING Pathway</title><p>The STING pathway is downstream of several nucleic acid sensors, including cGAS, ALRs, and DDXs. Recent studies have identified the degradation pathway for STING after it is activated, wherein ubiquitinated STING is targeted by hepatocyte growth factor-regulated tyrosine kinase substrate (HRS), a crucial component of the ESCRT-0 complex, resulting in its lysosomal degradation [<xref rid="B80-vaccines-13-00193" ref-type="bibr">80</xref>,<xref rid="B81-vaccines-13-00193" ref-type="bibr">81</xref>]. STING signaling is also terminated through the ESCRT-dependent microautophagy of vesicles originating from recycling endosomes [<xref rid="B82-vaccines-13-00193" ref-type="bibr">82</xref>].</p><p>There have been many reports regarding the recognition and regulation of DNA virus infection by the STING pathway [<xref rid="B83-vaccines-13-00193" ref-type="bibr">83</xref>]. STING pathway activation suppresses hepatitis B virus replication in human liver cell lines and in vivo mouse models [<xref rid="B84-vaccines-13-00193" ref-type="bibr">84</xref>], cytomegalovirus (CMV) replication in primary human endothelial cells [<xref rid="B85-vaccines-13-00193" ref-type="bibr">85</xref>], and HSV-1 replication in murine microglial cells [<xref rid="B86-vaccines-13-00193" ref-type="bibr">86</xref>]. DNA viruses have also evolved various strategies to antagonize the STING pathway and many evasion mechanisms and immunomodulators targeting the pathway have been identified [<xref rid="B83-vaccines-13-00193" ref-type="bibr">83</xref>]. For instance, the HSV-1 protein ICP27 interacts with the STING&#x02013;TBK1 complex to inhibit type I IFN induction [<xref rid="B87-vaccines-13-00193" ref-type="bibr">87</xref>]. The UL82 protein of human CMV impairs the translocation of STING from the ER to perinuclear microsomes and inhibits the recruitment of TBK1 and IRF3 to STING [<xref rid="B88-vaccines-13-00193" ref-type="bibr">88</xref>]. The EBV large tegument protein BPLF1 is a virulence factor that mitigates cGAS-induced IFN-&#x003b2; production by antagonizing IFN-&#x003b2; gene transcription through its deubiquitinase activity [<xref rid="B89-vaccines-13-00193" ref-type="bibr">89</xref>]; and the pseudorabies virus tegument protein UL13 inhibits antiviral responses by recruiting the E3 ligase RING-finger protein 5 to induce K27/K29-linked ubiquitination and degradation of STING, thereby suppressing STING-dependent signaling [<xref rid="B90-vaccines-13-00193" ref-type="bibr">90</xref>].</p><p>We recently discovered that in mice, one member of the ALR family, IFI207 (PYHINA), increases STING signaling by stabilizing it [<xref rid="B20-vaccines-13-00193" ref-type="bibr">20</xref>]. The <italic toggle="yes">Alr</italic> locus in mice has experienced rapid evolution over the past few million years, leading to the emergence of two novel members, <italic toggle="yes">MndaL</italic> and <italic toggle="yes">Ifi207</italic>. Notably, <italic toggle="yes">Ifi207</italic> in particular exhibits substantial genetic variation even among closely related inbred mouse strains. We found that IFI207 is unique among ALRs due to a large repeat region separating the N-terminal PYD and C-terminal HIN domains that plays a crucial role in stabilizing STING. While IFI207/STING interaction did not affect the cytokine response to bacterial infections (<italic toggle="yes">S. aureus</italic>, <italic toggle="yes">P. aeruginosa</italic>, and <italic toggle="yes">K. pneumoniae</italic>), it contributed to the control of in vivo MLV infection. IFI207 enhanced the STING signaling pathway, leading to an increased antiviral response by stabilizing STING protein [<xref rid="B20-vaccines-13-00193" ref-type="bibr">20</xref>]. Whether humans or other species also encode ALRs or other factors that stabilize STING remains to be determined, although IFI16 has been reported to have the opposite effect of destabilizing STING [<xref rid="B91-vaccines-13-00193" ref-type="bibr">91</xref>].</p></sec><sec id="sec7-vaccines-13-00193"><title>7. The Role of Intracellular Nucleic Acid Sensors in Vaccine Development</title><p>The common mechanism underlying all effective vaccines is that the activation of innate immune responses serves as a crucial initiating event that alters the outcome of the adaptive immune response [<xref rid="B92-vaccines-13-00193" ref-type="bibr">92</xref>,<xref rid="B93-vaccines-13-00193" ref-type="bibr">93</xref>,<xref rid="B94-vaccines-13-00193" ref-type="bibr">94</xref>]. Vaccines are thought to utilize two primary types of immune triggers. The first involves PAMPs derived from the target pathogen, while the second pertains to vaccine components, such as specific adjuvants, that induce the release of endogenous DAMPs. Both PAMPs and DAMPs stimulate the innate immune system by activating PRRs [<xref rid="B94-vaccines-13-00193" ref-type="bibr">94</xref>]. Signals derived from PRRs are integrated at the level of antigen-presenting cells (APCs), thereby effectively modulating the adaptive immune response to the vaccine [<xref rid="B94-vaccines-13-00193" ref-type="bibr">94</xref>,<xref rid="B95-vaccines-13-00193" ref-type="bibr">95</xref>].</p><p>Recently, adjuvants have been developed that include additional substances that stimulate PRRs, such as the TLR3 agonist polyinosinic:polycytidylic acid (poly I:C) [<xref rid="B7-vaccines-13-00193" ref-type="bibr">7</xref>]. Moreover, defective interfering particles (DIPs), which are non-infectious virions that typically encapsidate subgenomic viral RNA molecules and are naturally found in measles virus, poliovirus, and influenza vaccine preparations, activate both TLR3 and TLR7 and are also being tested as adjuvants [<xref rid="B7-vaccines-13-00193" ref-type="bibr">7</xref>]. CpG oligodeoxynucleotide (CpG ODN 1018), a 22-mer sequence with a modified phosphorothioate backbone, is the only TLR9 agonist utilized in an approved vaccine for use in humans, specifically in the licensed hepatitis B vaccine [<xref rid="B96-vaccines-13-00193" ref-type="bibr">96</xref>,<xref rid="B97-vaccines-13-00193" ref-type="bibr">97</xref>]. Inactivated whole-virus influenza vaccines do not contain any added adjuvants, but the viral genomic RNA present in the vaccine formulation is believed to exhibit strong adjuvant activity, whereas this effect is weaker in inactivated or split vaccines [<xref rid="B98-vaccines-13-00193" ref-type="bibr">98</xref>]. The combination of the synthetic dsRNA, poly I:C, and monophosphoryl lipid A (a TLR4 agonist) is under development as an adjuvant for influenza vaccines [<xref rid="B99-vaccines-13-00193" ref-type="bibr">99</xref>]. Furthermore, cyclic dinucleotides (CDNs), including those activating cGAS, are expected to be developed as vaccine adjuvants due to their ability to induce safe, potent, and long-lasting humoral and cellular memory responses in both systemic and mucosal compartments [<xref rid="B100-vaccines-13-00193" ref-type="bibr">100</xref>].</p><p>DNA vaccines, which include the adjuvant effect of DNA plasmids to enhance immune responses, generate immunogens in vivo which are presented to the immune system, while also activating PRRs that respond to DNA molecules [<xref rid="B101-vaccines-13-00193" ref-type="bibr">101</xref>,<xref rid="B102-vaccines-13-00193" ref-type="bibr">102</xref>,<xref rid="B103-vaccines-13-00193" ref-type="bibr">103</xref>]. Specifically, upon DNA vaccination, Aim2 knockout mice exhibit significantly reduced levels of IFN-&#x003b1;/&#x003b2;, along with diminished humoral and cellular antigen-specific adaptive responses, indicating that the inflammatory responses induced by Aim2 play a crucial role in DNA vaccine efficacy [<xref rid="B103-vaccines-13-00193" ref-type="bibr">103</xref>].</p><p>Some studies have reported that the STING pathway plays a crucial role as an intracellular sensor for DNA vaccines. Notably, cytosolic double-stranded DNA strongly induces IFN-I in both immune and non-immune cells through the STING pathway, likely via interaction with cGAS. The pathway operates independently of traditional TLRs and CpG motifs, suggesting that STING is a key sensor for the innate immune response to DNA vaccines [<xref rid="B103-vaccines-13-00193" ref-type="bibr">103</xref>,<xref rid="B104-vaccines-13-00193" ref-type="bibr">104</xref>,<xref rid="B105-vaccines-13-00193" ref-type="bibr">105</xref>]. However, although it has been proposed that STING agonists might make good vaccine adjuvants, none are in clinical trials as of yet [<xref rid="B106-vaccines-13-00193" ref-type="bibr">106</xref>].</p><p>The advent of mRNA vaccines, particularly highlighted during the COVID-19 pandemic, has revolutionized vaccine technology by introducing viral genetic material into host cells to activate the innate immune system. The two key components of the currently approved mRNA vaccines for COVID-19 are nucleoside-modified mRNAs that encode the antigenic protein and lipid nanoparticles (iLNPs) containing ionizable lipids that facilitate the efficient delivery of intact mRNA to the cytoplasm of cells [<xref rid="B3-vaccines-13-00193" ref-type="bibr">3</xref>,<xref rid="B4-vaccines-13-00193" ref-type="bibr">4</xref>].</p></sec><sec id="sec8-vaccines-13-00193"><title>8. mRNA Vaccines and the Recognition Mechanisms of Non-Self RNA</title><p>mRNA vaccines can also stimulate innate immunity through TLRs (TLR3, 7, and 8) and the RLRs (RIG-I and MDA5) [<xref rid="B107-vaccines-13-00193" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-13-00193" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-13-00193" ref-type="bibr">109</xref>]. RIG-I recognizes ssRNA and dsRNA bearing a 5-triphosphates, stimulating IFN-I production [<xref rid="B109-vaccines-13-00193" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-13-00193" ref-type="bibr">110</xref>]. In contrast, MDA5 detects long dsRNA generated during RNA virus replication, as well as synthetic RNAs, including poly I:C; the recognition of dsRNA by MDA5 activates IRF3 and NF&#x003ba;B, also leading to increased production of IFN-I [<xref rid="B109-vaccines-13-00193" ref-type="bibr">109</xref>,<xref rid="B110-vaccines-13-00193" ref-type="bibr">110</xref>] (<xref rid="vaccines-13-00193-f002" ref-type="fig">Figure 2</xref>).</p><p>However, excessive activation of immune responses may compromise the safety of mRNA vaccines, highlighting the importance of understanding the distinctions between self and non-self mRNA structures. Notably, insights into this distinction have paved the way for RNA modification techniques [<xref rid="B111-vaccines-13-00193" ref-type="bibr">111</xref>]. Specifically, the recognition of non-self-nucleic acids is based on their structure, availability, and localization. Self-nucleic acids are typically degraded by nucleases before they can be sensed by nucleic acid receptors, preventing their recognition. In contrast, nucleic acid receptors recognize structural features characteristic of non-self RNAs, such as long dsRNA and 5&#x02032;-triphosphate or 5&#x02032;-diphosphate dsRNA, which trigger antiviral immune responses through these structural motifs [<xref rid="B112-vaccines-13-00193" ref-type="bibr">112</xref>]. In mRNA vaccines, modifications to structural elements such as the 5&#x02032; cap, 5&#x02032;-and 3&#x02032;-untranslated regions, coding region, and poly(A) tail prevent its recognition and degradation as non-self RNA by the immune system [<xref rid="B113-vaccines-13-00193" ref-type="bibr">113</xref>].</p><p>Furthermore, the dsRNA produced during in vitro is recognized in cells by PRRs such as TLR3 and RLRs, leading to the induction of IFN-I [<xref rid="B106-vaccines-13-00193" ref-type="bibr">106</xref>,<xref rid="B107-vaccines-13-00193" ref-type="bibr">107</xref>,<xref rid="B108-vaccines-13-00193" ref-type="bibr">108</xref>,<xref rid="B109-vaccines-13-00193" ref-type="bibr">109</xref>], as well as by protein kinase R leading to activation of the PKR&#x02013;eIF2&#x003b1; pathway, which inhibits both cellular and viral translation, leading to apoptosis and thereby triggering the stress response [<xref rid="B114-vaccines-13-00193" ref-type="bibr">114</xref>]. Incorporation of pseudouridine and 2-thiouridine prevents the recognition of in vitro transcribed mRNA by TLR, RIG-I, and PKR, thereby improving vaccine effectiveness and minimizing the risk of inflammatory responses [<xref rid="B115-vaccines-13-00193" ref-type="bibr">115</xref>,<xref rid="B116-vaccines-13-00193" ref-type="bibr">116</xref>,<xref rid="B117-vaccines-13-00193" ref-type="bibr">117</xref>,<xref rid="B118-vaccines-13-00193" ref-type="bibr">118</xref>,<xref rid="B119-vaccines-13-00193" ref-type="bibr">119</xref>].</p><p>The mRNA cap structure is a major site of dynamic mRNA methylation and is classified into either Cap1 or Cap2 structures depending on whether the first transcribed nucleotide, or both the first and second transcribed nucleotides, are 2&#x02032;-O-methylated [<xref rid="B120-vaccines-13-00193" ref-type="bibr">120</xref>]. The Cap1 structure on mRNA serves as an important marker for distinguishing self RNA from non-self RNAs such as viral RNAs which lack a cap, and by evading recognition by RLRs, viruses can effectively escape immune detection [<xref rid="B121-vaccines-13-00193" ref-type="bibr">121</xref>]. The dual methylation in Cap2 inhibits the binding of Cap1 to RIG-I, thereby suppressing the ability of endogenous RNA to activate the innate immune response [<xref rid="B120-vaccines-13-00193" ref-type="bibr">120</xref>].</p><p>In summary, these modifications when engineered into RNA vaccines enhance RNA stability, improve translation efficiency, and reduce the overall immunogenic response associated with RNA vaccines. While RNA modification techniques are important for enhancing RNA stability and modulating immunogenicity, the cytosolic sensors are also critical for ensuring the safety and efficacy of mRNA vaccines.</p></sec><sec sec-type="conclusions" id="sec9-vaccines-13-00193"><title>9. Conclusions</title><p>Cytosolic sensors regulate nucleic acid recognition and signaling pathways to appropriately control immune responses. Through these mechanisms, cells have evolved a multi-layered system to detect virus-derived components that serve as PAMPs, suppressing viral infection at an early stage via the innate immune system and facilitating the transition to adaptive immune responses. Thus, the mammalian innate immune system utilizes multiple PRRs to effectively control and eliminate viral infections, demonstrating sophisticated evolutionary adaptation.</p><p>Advancements in the understanding of cytosolic sensors and signaling mechanisms are essential for the development of effective and safe vaccines. Intracellular nucleic acid sensors are integral to the immunogenicity of live attenuated, killed, and nucleic acid-based vaccines. Their roles in mediating immune responses form the foundation for developing innovative strategies to enhance vaccine efficacy, facilitating the design of next-generation vaccines against infectious diseases and cancer. At the same time, the use of these molecules as adjuvants could lead to the excessive, uncontrolled activation of innate immune responses that may compromise vaccine safety. Future research is anticipated to further refine vaccine design based on these pathways, leading to more robust and sustained immune responses while minimizing untoward side effects.</p></sec></body><back><ack><title>Acknowledgments</title><p>We apologize for being unable to cite all the excellent papers on this subject. We thank Masaaki Miyazawa for their helpful comments on the manuscript.</p></ack><fn-group><fn><p><bold>Disclaimer/Publisher&#x02019;s Note:</bold> The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.</p></fn></fn-group><notes><title>Author Contributions</title><p>T.E.: Conceptualization; writing&#x02014;review and editing; writing&#x02014;original draft. S.R.R.: Conceptualization; writing&#x02014;review and editing; funding acquisition; supervision. All authors have read and agreed to the published version of the manuscript.</p></notes><notes notes-type="COI-statement"><title>Conflicts of Interest</title><p>The authors declare no conflicts of interest.</p></notes><ref-list><title>References</title><ref id="B1-vaccines-13-00193"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Guy</surname><given-names>C.</given-names></name>
<name><surname>Bowie</surname><given-names>A.G.</given-names></name>
</person-group><article-title>Recent insights into innate immune nucleic acid sensing during viral infection</article-title><source>Curr. Opin. Immunol.</source><year>2022</year><volume>78</volume><fpage>102250</fpage><pub-id pub-id-type="doi">10.1016/j.coi.2022.102250</pub-id><pub-id pub-id-type="pmid">36209576</pub-id>
</element-citation></ref><ref id="B2-vaccines-13-00193"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pardi</surname><given-names>N.</given-names></name>
<name><surname>Hogan</surname><given-names>M.J.</given-names></name>
<name><surname>Porter</surname><given-names>F.W.</given-names></name>
<name><surname>Weissman</surname><given-names>D.</given-names></name>
</person-group><article-title>mRNA vaccines&#x02014;A new era in vaccinology</article-title><source>Nat. Rev. Drug Discov.</source><year>2018</year><volume>17</volume><fpage>261</fpage><lpage>279</lpage><pub-id pub-id-type="doi">10.1038/nrd.2017.243</pub-id><pub-id pub-id-type="pmid">29326426</pub-id>
</element-citation></ref><ref id="B3-vaccines-13-00193"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cullis</surname><given-names>P.R.</given-names></name>
<name><surname>Hope</surname><given-names>M.J.</given-names></name>
</person-group><article-title>Lipid Nanoparticle Systems for Enabling Gene Therapies</article-title><source>Mol. Ther.</source><year>2017</year><volume>25</volume><fpage>1467</fpage><lpage>1475</lpage><pub-id pub-id-type="doi">10.1016/j.ymthe.2017.03.013</pub-id><pub-id pub-id-type="pmid">28412170</pub-id>
</element-citation></ref><ref id="B4-vaccines-13-00193"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Verbeke</surname><given-names>R.</given-names></name>
<name><surname>Hogan</surname><given-names>M.J.</given-names></name>
<name><surname>Lor&#x000e9;</surname><given-names>K.</given-names></name>
<name><surname>Pardi</surname><given-names>N.</given-names></name>
</person-group><article-title>Innate immune mechanisms of mRNA vaccines</article-title><source>Immunity</source><year>2022</year><volume>55</volume><fpage>1993</fpage><lpage>2005</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2022.10.014</pub-id><pub-id pub-id-type="pmid">36351374</pub-id>
</element-citation></ref><ref id="B5-vaccines-13-00193"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lint</surname><given-names>S.V.</given-names></name>
<name><surname>Renmans</surname><given-names>D.</given-names></name>
<name><surname>Broos</surname><given-names>K.</given-names></name>
<name><surname>Dewitte</surname><given-names>H.</given-names></name>
<name><surname>Lentacker</surname><given-names>I.</given-names></name>
<name><surname>Heirman</surname><given-names>C.</given-names></name>
<name><surname>Breckpot</surname><given-names>K.</given-names></name>
<name><surname>Thielemans</surname><given-names>K.</given-names></name>
</person-group><article-title>The ReNAissanCe of mRNA-based cancer therapy</article-title><source>Expert Rev. Vaccines</source><year>2015</year><volume>14</volume><fpage>235</fpage><lpage>251</lpage><pub-id pub-id-type="doi">10.1586/14760584.2015.957685</pub-id><pub-id pub-id-type="pmid">25263094</pub-id>
</element-citation></ref><ref id="B6-vaccines-13-00193"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Edwards</surname><given-names>D.K.</given-names></name>
<name><surname>Jasny</surname><given-names>E.</given-names></name>
<name><surname>Yoon</surname><given-names>H.</given-names></name>
<name><surname>Horscroft</surname><given-names>N.</given-names></name>
<name><surname>Schanen</surname><given-names>B.</given-names></name>
<name><surname>Geter</surname><given-names>T.</given-names></name>
<name><surname>Fotin Mleczek</surname><given-names>M.</given-names></name>
<name><surname>Petsch</surname><given-names>B.</given-names></name>
<name><surname>Wittman</surname><given-names>V.</given-names></name>
</person-group><article-title>Adjuvant effects of a sequence-engineered mRNA vaccine: Translational profiling demonstrates similar human and murine innate response</article-title><source>J. Transl. Med.</source><year>2017</year><volume>15</volume><fpage>1</fpage><lpage>18</lpage><pub-id pub-id-type="doi">10.1186/s12967-016-1111-6</pub-id><pub-id pub-id-type="pmid">28049494</pub-id>
</element-citation></ref><ref id="B7-vaccines-13-00193"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Vasou</surname><given-names>A.</given-names></name>
<name><surname>Sultanoglu</surname><given-names>N.</given-names></name>
<name><surname>Goodbourn</surname><given-names>S.</given-names></name>
<name><surname>Randall</surname><given-names>R.E.</given-names></name>
<name><surname>Kostrikis</surname><given-names>L.G.</given-names></name>
</person-group><article-title>Targeting Pattern Recognition Receptors (PRR) for Vaccine Adjuvantation: From Synthetic PRR Agonists to the Potential of Defective Interfering Particles of Viruses</article-title><source>Viruses</source><year>2017</year><volume>9</volume><elocation-id>186</elocation-id><pub-id pub-id-type="doi">10.3390/v9070186</pub-id><pub-id pub-id-type="pmid">28703784</pub-id>
</element-citation></ref><ref id="B8-vaccines-13-00193"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hennessy</surname><given-names>C.</given-names></name>
<name><surname>McKernan</surname><given-names>D.P.</given-names></name>
</person-group><article-title>Anti-Viral Pattern Recognition Receptors as Therapeutic Targets</article-title><source>Cells</source><year>2021</year><volume>10</volume><elocation-id>2258</elocation-id><pub-id pub-id-type="doi">10.3390/cells10092258</pub-id><pub-id pub-id-type="pmid">34571909</pub-id>
</element-citation></ref><ref id="B9-vaccines-13-00193"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Akira</surname><given-names>S.</given-names></name>
<name><surname>Uematsu</surname><given-names>S.</given-names></name>
<name><surname>Takeuchi</surname><given-names>O.</given-names></name>
</person-group><article-title>Pathogen Recognition and Innate Immunity</article-title><source>Cell</source><year>2006</year><volume>124</volume><fpage>783</fpage><lpage>801</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2006.02.015</pub-id><pub-id pub-id-type="pmid">16497588</pub-id>
</element-citation></ref><ref id="B10-vaccines-13-00193"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Loo</surname><given-names>Y.M.</given-names></name>
<name><surname>Gale</surname><given-names>M.</given-names><suffix>Jr.</suffix></name>
</person-group><article-title>Immune signaling by RIG-I-like receptors</article-title><source>Immunity</source><year>2011</year><volume>34</volume><fpage>680</fpage><lpage>692</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2011.05.003</pub-id><pub-id pub-id-type="pmid">21616437</pub-id>
</element-citation></ref><ref id="B11-vaccines-13-00193"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bhat</surname><given-names>N.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>K.A.</given-names></name>
</person-group><article-title>Recognition of Cytosolic DNA by cGAS and other STING dependent sensors</article-title><source>Eur. J. Immunol.</source><year>2014</year><volume>44</volume><fpage>634</fpage><lpage>640</lpage><pub-id pub-id-type="doi">10.1002/eji.201344127</pub-id><pub-id pub-id-type="pmid">24356864</pub-id>
</element-citation></ref><ref id="B12-vaccines-13-00193"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Schattgen</surname><given-names>S.A.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>K.A.</given-names></name>
</person-group><article-title>The PYHIN protein family as mediators of host defenses</article-title><source>Immunol. Rev.</source><year>2011</year><volume>243</volume><fpage>109</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1111/j.1600-065X.2011.01053.x</pub-id><pub-id pub-id-type="pmid">21884171</pub-id>
</element-citation></ref><ref id="B13-vaccines-13-00193"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kawai</surname><given-names>T.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
</person-group><article-title>The role of pattern-recognition receptors in innate immunity: Update on Toll-like receptors</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>373</fpage><lpage>384</lpage><pub-id pub-id-type="doi">10.1038/ni.1863</pub-id><pub-id pub-id-type="pmid">20404851</pub-id>
</element-citation></ref><ref id="B14-vaccines-13-00193"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Decker</surname><given-names>T.</given-names></name>
<name><surname>Stockinger</surname><given-names>S.</given-names></name>
<name><surname>Karaghiosoff</surname><given-names>M.</given-names></name>
<name><surname>Muller</surname><given-names>M.</given-names></name>
<name><surname>Kovarik</surname><given-names>P.</given-names></name>
</person-group><article-title>IFNs and STATs in innate immunity to microorganisms</article-title><source>J. Clin. Investig.</source><year>2002</year><volume>109</volume><fpage>1271</fpage><lpage>1277</lpage><pub-id pub-id-type="doi">10.1172/JCI0215770</pub-id><pub-id pub-id-type="pmid">12021240</pub-id>
</element-citation></ref><ref id="B15-vaccines-13-00193"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bose</surname><given-names>S.</given-names></name>
<name><surname>Banerjee</surname><given-names>A.K.</given-names></name>
</person-group><article-title>Innate immune response against nonsegmented negative strand RNA viruses</article-title><source>J. Interferon Cytokine Res.</source><year>2003</year><volume>23</volume><fpage>401</fpage><lpage>412</lpage><pub-id pub-id-type="doi">10.1089/107999003322277810</pub-id><pub-id pub-id-type="pmid">13678428</pub-id>
</element-citation></ref><ref id="B16-vaccines-13-00193"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rehwinkel</surname><given-names>J.</given-names></name>
<name><surname>Gack</surname><given-names>M.U.</given-names></name>
</person-group><article-title>RIG-I-like receptors: Their regulation and roles in RNA sensing</article-title><source>Nat. Rev. Immunol.</source><year>2020</year><volume>20</volume><fpage>537</fpage><lpage>551</lpage><pub-id pub-id-type="doi">10.1038/s41577-020-0288-3</pub-id><pub-id pub-id-type="pmid">32203325</pub-id>
</element-citation></ref><ref id="B17-vaccines-13-00193"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Chiang</surname><given-names>C.</given-names></name>
<name><surname>Gack</surname><given-names>M.U.</given-names></name>
</person-group><article-title>Viral evasion of the interferon response at a glance</article-title><source>J. Cell Sci.</source><year>2023</year><volume>136</volume><fpage>jcs260682</fpage><pub-id pub-id-type="doi">10.1242/jcs.260682</pub-id><pub-id pub-id-type="pmid">37341132</pub-id>
</element-citation></ref><ref id="B18-vaccines-13-00193"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cridland</surname><given-names>J.A.</given-names></name>
<name><surname>Curley</surname><given-names>E.Z.</given-names></name>
<name><surname>Wykes</surname><given-names>M.N.</given-names></name>
<name><surname>Schroder</surname><given-names>K.</given-names></name>
<name><surname>Sweet</surname><given-names>M.J.</given-names></name>
<name><surname>Roberts</surname><given-names>T.L.</given-names></name>
<name><surname>Ragan</surname><given-names>M.A.</given-names></name>
<name><surname>Kassahn</surname><given-names>K.S.</given-names></name>
<name><surname>Stacey</surname><given-names>K.J.</given-names></name>
</person-group><article-title>The mammalian PYHIN gene family: Phylogeny, evolution and expression</article-title><source>BMC Evol. Biol.</source><year>2012</year><volume>12</volume><elocation-id>140</elocation-id><pub-id pub-id-type="doi">10.1186/1471-2148-12-140</pub-id><pub-id pub-id-type="pmid">22871040</pub-id>
</element-citation></ref><ref id="B19-vaccines-13-00193"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Phillips</surname><given-names>K.P.</given-names></name>
<name><surname>Cable</surname><given-names>J.</given-names></name>
<name><surname>Mohammed</surname><given-names>R.S.</given-names></name>
<name><surname>Herdegen-Radwan</surname><given-names>M.</given-names></name>
<name><surname>Raubic</surname><given-names>J.</given-names></name>
<name><surname>Przesmycka</surname><given-names>K.J.</given-names></name>
<name><surname>van Oosterhout</surname><given-names>C.</given-names></name>
<name><surname>Radwan</surname><given-names>J.</given-names></name>
</person-group><article-title>Immunogenetic novelty confers a selective advantage in host-pathogen coevolution</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2018</year><volume>115</volume><fpage>1552</fpage><lpage>1557</lpage><pub-id pub-id-type="doi">10.1073/pnas.1708597115</pub-id><pub-id pub-id-type="pmid">29339521</pub-id>
</element-citation></ref><ref id="B20-vaccines-13-00193"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moran</surname><given-names>E.A.</given-names></name>
<name><surname>Salas-Briceno</surname><given-names>K.</given-names></name>
<name><surname>Zhao</surname><given-names>W.</given-names></name>
<name><surname>Enya</surname><given-names>T.</given-names></name>
<name><surname>Aguilera</surname><given-names>A.N.</given-names></name>
<name><surname>Acosta</surname><given-names>I.</given-names></name>
<name><surname>Alonzo</surname><given-names>F.</given-names></name>
<name><surname>Kiani</surname><given-names>D.</given-names></name>
<name><surname>Behnsen</surname><given-names>J.</given-names></name>
<name><surname>Alvarez</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>IFI207, a young and fast-evolving protein, controls retroviral replication via the STING pathway</article-title><source>mBio</source><year>2024</year><volume>15</volume><elocation-id>e01209-24</elocation-id><pub-id pub-id-type="doi">10.1128/mbio.01209-24</pub-id><pub-id pub-id-type="pmid">38860764</pub-id>
</element-citation></ref><ref id="B21-vaccines-13-00193"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Melepat</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>T.</given-names></name>
<name><surname>Vinkler</surname><given-names>M.</given-names></name>
</person-group><article-title>Natural selection directing molecular evolution in vertebrate viral sensors</article-title><source>Dev. Comp. Immunol.</source><year>2024</year><volume>154</volume><fpage>105147</fpage><pub-id pub-id-type="doi">10.1016/j.dci.2024.105147</pub-id><pub-id pub-id-type="pmid">38325501</pub-id>
</element-citation></ref><ref id="B22-vaccines-13-00193"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brubaker</surname><given-names>S.W.</given-names></name>
<name><surname>Bonham</surname><given-names>K.S.</given-names></name>
<name><surname>Zanoni</surname><given-names>I.</given-names></name>
<name><surname>Kagan</surname><given-names>J.C.</given-names></name>
</person-group><article-title>Innate immune pattern recognition: A cell biological perspective</article-title><source>Annu. Rev. Immunol.</source><year>2015</year><volume>33</volume><fpage>257</fpage><lpage>290</lpage><pub-id pub-id-type="doi">10.1146/annurev-immunol-032414-112240</pub-id><pub-id pub-id-type="pmid">25581309</pub-id>
</element-citation></ref><ref id="B23-vaccines-13-00193"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Yarovinsky</surname><given-names>F.</given-names></name>
<name><surname>Zhang</surname><given-names>D.</given-names></name>
<name><surname>Andersen</surname><given-names>J.F.</given-names></name>
<name><surname>Bannenberg</surname><given-names>G.L.</given-names></name>
<name><surname>Serhan</surname><given-names>C.N.</given-names></name>
<name><surname>Hayden</surname><given-names>M.S.</given-names></name>
<name><surname>Hieny</surname><given-names>S.</given-names></name>
<name><surname>Sutterwala</surname><given-names>F.S.</given-names></name>
<name><surname>Flavell</surname><given-names>R.A.</given-names></name>
<name><surname>Ghosh</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>TLR11 Activation of Dendritic Cells by a Protozoan Profilin-like Protein</article-title><source>Science</source><year>2005</year><volume>308</volume><fpage>1626</fpage><lpage>1629</lpage><pub-id pub-id-type="doi">10.1126/science.1109893</pub-id><pub-id pub-id-type="pmid">15860593</pub-id>
</element-citation></ref><ref id="B24-vaccines-13-00193"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhou</surname><given-names>S.</given-names></name>
<name><surname>Halle</surname><given-names>A.</given-names></name>
<name><surname>Kurt-Jones</surname><given-names>E.A.</given-names></name>
<name><surname>Cerny</surname><given-names>A.M.</given-names></name>
<name><surname>Porpiglia</surname><given-names>E.</given-names></name>
<name><surname>Rogers</surname><given-names>M.</given-names></name>
<name><surname>Golenbock</surname><given-names>D.T.</given-names></name>
<name><surname>Finberg</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Lymphocytic choriomeningitis virus (LCMV) infection of CNS glial cells results in TLR2-MyD88/Mal-dependent inflammatory responses</article-title><source>J. Neuroimmunol.</source><year>2008</year><volume>194</volume><fpage>70</fpage><lpage>82</lpage><pub-id pub-id-type="doi">10.1016/j.jneuroim.2007.11.018</pub-id><pub-id pub-id-type="pmid">18295350</pub-id>
</element-citation></ref><ref id="B25-vaccines-13-00193"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cuevas</surname><given-names>C.D.</given-names></name>
<name><surname>Ross</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Toll-like receptor 2-mediated innate immune responses against Jun&#x000ed;n virus in mice lead to antiviral adaptive immune responses during systemic infection and do not affect viral replication in the brain</article-title><source>J. Virol.</source><year>2014</year><volume>88</volume><fpage>7703</fpage><lpage>7714</lpage><pub-id pub-id-type="doi">10.1128/JVI.00050-14</pub-id><pub-id pub-id-type="pmid">24760892</pub-id>
</element-citation></ref><ref id="B26-vaccines-13-00193"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bieback</surname><given-names>K.</given-names></name>
<name><surname>Lien</surname><given-names>E.</given-names></name>
<name><surname>Klagge</surname><given-names>I.M.</given-names></name>
<name><surname>Avota</surname><given-names>E.</given-names></name>
<name><surname>Schneider-Schaulies</surname><given-names>J.</given-names></name>
<name><surname>Duprex</surname><given-names>W.P.</given-names></name>
<name><surname>Wagner</surname><given-names>H.</given-names></name>
<name><surname>Kirschning</surname><given-names>C.J.</given-names></name>
<name><surname>Ter Meulen</surname><given-names>V.</given-names></name>
<name><surname>Schneider-Schaulies</surname><given-names>S.</given-names></name>
</person-group><article-title>Hemagglutinin protein of wild-type measles virus activates toll-like receptor 2 signaling</article-title><source>J. Virol.</source><year>2002</year><volume>76</volume><fpage>8729</fpage><lpage>8736</lpage><pub-id pub-id-type="doi">10.1128/JVI.76.17.8729-8736.2002</pub-id><pub-id pub-id-type="pmid">12163593</pub-id>
</element-citation></ref><ref id="B27-vaccines-13-00193"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Murawski</surname><given-names>M.R.</given-names></name>
<name><surname>Bowen</surname><given-names>G.N.</given-names></name>
<name><surname>Cerny</surname><given-names>A.M.</given-names></name>
<name><surname>Anderson</surname><given-names>L.J.</given-names></name>
<name><surname>Haynes</surname><given-names>L.M.</given-names></name>
<name><surname>Tripp</surname><given-names>R.A.</given-names></name>
<name><surname>Kurt-Jones</surname><given-names>E.A.</given-names></name>
<name><surname>Finberg</surname><given-names>R.W.</given-names></name>
</person-group><article-title>Respiratory syncytial virus activates innate immunity through Toll-like receptor 2</article-title><source>J. Virol.</source><year>2009</year><volume>83</volume><fpage>1492</fpage><lpage>1500</lpage><pub-id pub-id-type="doi">10.1128/JVI.00671-08</pub-id><pub-id pub-id-type="pmid">19019963</pub-id>
</element-citation></ref><ref id="B28-vaccines-13-00193"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Aravalli</surname><given-names>R.N.</given-names></name>
<name><surname>Hu</surname><given-names>S.</given-names></name>
<name><surname>Rowen</surname><given-names>T.N.</given-names></name>
<name><surname>Palmquist</surname><given-names>J.M.</given-names></name>
<name><surname>Lokensgard</surname><given-names>J.R.</given-names></name>
</person-group><article-title>Cutting Edge: TLR2-Mediated Proinflammatory Cytokine and Chemokine Production by Microglial Cells in Response to Herpes Simplex Virus</article-title><source>J. Immunol.</source><year>2005</year><volume>175</volume><fpage>4189</fpage><lpage>4193</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.175.7.4189</pub-id><pub-id pub-id-type="pmid">16177057</pub-id>
</element-citation></ref><ref id="B29-vaccines-13-00193"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Alexopoulou</surname><given-names>L.</given-names></name>
<name><surname>Holt</surname><given-names>A.C.</given-names></name>
<name><surname>Medzhitov</surname><given-names>R.</given-names></name>
<name><surname>Flavell</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Recognition of double-stranded RNA and activation of NF-&#x003ba;B by Toll-like receptor 3</article-title><source>Nature</source><year>2001</year><volume>413</volume><fpage>732</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1038/35099560</pub-id><pub-id pub-id-type="pmid">11607032</pub-id>
</element-citation></ref><ref id="B30-vaccines-13-00193"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tabeta</surname><given-names>K.</given-names></name>
<name><surname>Georgel</surname><given-names>P.</given-names></name>
<name><surname>Janssen</surname><given-names>E.</given-names></name>
<name><surname>Du</surname><given-names>X.</given-names></name>
<name><surname>Hoebe</surname><given-names>K.</given-names></name>
<name><surname>Crozat</surname><given-names>K.</given-names></name>
<name><surname>Mudd</surname><given-names>S.</given-names></name>
<name><surname>Shamel</surname><given-names>L.</given-names></name>
<name><surname>Sovath</surname><given-names>S.</given-names></name>
<name><surname>Goode</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Toll-like receptors 9 and 3 as essential components of innate immune defense against mouse cytomegalovirus infection</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>3516</fpage><lpage>3521</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400525101</pub-id><pub-id pub-id-type="pmid">14993594</pub-id>
</element-citation></ref><ref id="B31-vaccines-13-00193"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Town</surname><given-names>T.</given-names></name>
<name><surname>Alexopoulou</surname><given-names>L.</given-names></name>
<name><surname>Anderson</surname><given-names>J.F.</given-names></name>
<name><surname>Fikrig</surname><given-names>E.</given-names></name>
<name><surname>Flavell</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Toll-like receptor 3 mediates West Nile virus entry into the brain causing lethal encephalitis</article-title><source>Nat. Med.</source><year>2004</year><volume>10</volume><fpage>1366</fpage><lpage>1373</lpage><pub-id pub-id-type="doi">10.1038/nm1140</pub-id><pub-id pub-id-type="pmid">15558055</pub-id>
</element-citation></ref><ref id="B32-vaccines-13-00193"><label>32.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goffic</surname><given-names>R.L.</given-names></name>
<name><surname>Balloy</surname><given-names>V.</given-names></name>
<name><surname>Lagranderie</surname><given-names>M.</given-names></name>
<name><surname>Alexopoulou</surname><given-names>L.</given-names></name>
<name><surname>Escriou</surname><given-names>N.</given-names></name>
<name><surname>Flavell</surname><given-names>R.</given-names></name>
<name><surname>Chignard</surname><given-names>M.</given-names></name>
<name><surname>Si-Tahar</surname><given-names>M.</given-names></name>
</person-group><article-title>Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia</article-title><source>PLoS Pathog.</source><year>2006</year><volume>2</volume><elocation-id>e53</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.0020053</pub-id><pub-id pub-id-type="pmid">16789835</pub-id>
</element-citation></ref><ref id="B33-vaccines-13-00193"><label>33.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reinert</surname><given-names>L.S.</given-names></name>
<name><surname>Harder</surname><given-names>L.</given-names></name>
<name><surname>Holm</surname><given-names>C.K.</given-names></name>
<name><surname>Iversen</surname><given-names>M.B.</given-names></name>
<name><surname>Horan</surname><given-names>K.A.</given-names></name>
<name><surname>Dagn&#x000e6;s-Hansen</surname><given-names>F.</given-names></name>
<name><surname>Ulh&#x000f8;i</surname><given-names>B.P.</given-names></name>
<name><surname>Holm</surname><given-names>T.H.</given-names></name>
<name><surname>Mogensen</surname><given-names>T.H.</given-names></name>
<name><surname>Owens</surname><given-names>T.</given-names></name>
<etal/>
</person-group><article-title>TLR3 deficiency renders astrocytes permissive to herpes simplex virus infection and facilitates establishment of CNS infection in mice</article-title><source>J. Clin. Investig.</source><year>2012</year><volume>122</volume><fpage>1368</fpage><lpage>1376</lpage><pub-id pub-id-type="doi">10.1172/JCI60893</pub-id><pub-id pub-id-type="pmid">22426207</pub-id>
</element-citation></ref><ref id="B34-vaccines-13-00193"><label>34.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Diebold</surname><given-names>S.S.</given-names></name>
<name><surname>Kaisho</surname><given-names>T.</given-names></name>
<name><surname>Hemmi</surname><given-names>H.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<name><surname>Sousa</surname><given-names>C.R.E.</given-names></name>
</person-group><article-title>Innate Antiviral Responses by Means of TLR7-Mediated Recognition of Single-Stranded RNA</article-title><source>Science</source><year>2004</year><volume>303</volume><fpage>1529</fpage><lpage>1531</lpage><pub-id pub-id-type="doi">10.1126/science.1093616</pub-id><pub-id pub-id-type="pmid">14976261</pub-id>
</element-citation></ref><ref id="B35-vaccines-13-00193"><label>35.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lund</surname><given-names>J.M.</given-names></name>
<name><surname>Alexopoulou</surname><given-names>L.</given-names></name>
<name><surname>Sato</surname><given-names>A.</given-names></name>
<name><surname>Karow</surname><given-names>M.</given-names></name>
<name><surname>Adams</surname><given-names>N.C.</given-names></name>
<name><surname>Gale</surname><given-names>N.W.</given-names></name>
<name><surname>Iwasaki</surname><given-names>A.</given-names></name>
<name><surname>Flavell</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Recognition of single-stranded RNA viruses by Toll-like receptor 7</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2004</year><volume>101</volume><fpage>5598</fpage><lpage>5603</lpage><pub-id pub-id-type="doi">10.1073/pnas.0400937101</pub-id><pub-id pub-id-type="pmid">15034168</pub-id>
</element-citation></ref><ref id="B36-vaccines-13-00193"><label>36.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Town</surname><given-names>T.</given-names></name>
<name><surname>Bai</surname><given-names>F.</given-names></name>
<name><surname>Wang</surname><given-names>T.</given-names></name>
<name><surname>Kaplan</surname><given-names>A.T.</given-names></name>
<name><surname>Qian</surname><given-names>F.</given-names></name>
<name><surname>Montgomery</surname><given-names>R.R.</given-names></name>
<name><surname>Anderson</surname><given-names>J.F.</given-names></name>
<name><surname>Flavell</surname><given-names>R.A.</given-names></name>
<name><surname>Fikrig</surname><given-names>E.</given-names></name>
</person-group><article-title>Toll-like receptor 7 mitigates lethal West Nile encephalitis via interleukin 23-dependent immune cell infiltration and homing</article-title><source>Immunity</source><year>2009</year><volume>30</volume><fpage>242</fpage><lpage>253</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.11.012</pub-id><pub-id pub-id-type="pmid">19200759</pub-id>
</element-citation></ref><ref id="B37-vaccines-13-00193"><label>37.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Heil</surname><given-names>F.</given-names></name>
<name><surname>Hemmi</surname><given-names>H.</given-names></name>
<name><surname>Hochrein</surname><given-names>H.</given-names></name>
<name><surname>Ampenberger</surname><given-names>F.</given-names></name>
<name><surname>Kirschning</surname><given-names>C.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<name><surname>Lipford</surname><given-names>G.</given-names></name>
<name><surname>Wagner</surname><given-names>H.</given-names></name>
<name><surname>Bauer</surname><given-names>S.</given-names></name>
</person-group><article-title>Species-Specific Recognition of Single-Stranded RNA via Tolllike Receptor 7 and 8</article-title><source>Science</source><year>2004</year><volume>303</volume><fpage>1526</fpage><lpage>1529</lpage><pub-id pub-id-type="doi">10.1126/science.1093620</pub-id><pub-id pub-id-type="pmid">14976262</pub-id>
</element-citation></ref><ref id="B38-vaccines-13-00193"><label>38.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Krug</surname><given-names>A.</given-names></name>
<name><surname>Luker</surname><given-names>G.D.</given-names></name>
<name><surname>Barchet</surname><given-names>W.</given-names></name>
<name><surname>Leib</surname><given-names>D.A.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<name><surname>Colonna</surname><given-names>M.</given-names></name>
</person-group><article-title>Herpes simplex virus type 1 activates murine natural interferon-producing cells through toll-like receptor 9</article-title><source>Blood</source><year>2004</year><volume>103</volume><fpage>1433</fpage><lpage>1437</lpage><pub-id pub-id-type="doi">10.1182/blood-2003-08-2674</pub-id><pub-id pub-id-type="pmid">14563635</pub-id>
</element-citation></ref><ref id="B39-vaccines-13-00193"><label>39.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Samuelsson</surname><given-names>C.</given-names></name>
<name><surname>Hausmann</surname><given-names>J.</given-names></name>
<name><surname>Lauterbach</surname><given-names>H.</given-names></name>
<name><surname>Schmidt</surname><given-names>M.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<name><surname>Wagner</surname><given-names>H.</given-names></name>
<name><surname>Chaplin</surname><given-names>P.</given-names></name>
<name><surname>Suter</surname><given-names>M.</given-names></name>
<name><surname>O&#x02019;Keeffe</surname><given-names>M.</given-names></name>
<name><surname>Hochrein</surname><given-names>H.</given-names></name>
</person-group><article-title>Survival of lethal poxvirus infection in mice depends on TLR9, and therapeutic vaccination provides protection</article-title><source>J. Clin. Invest.</source><year>2008</year><volume>118</volume><fpage>1776</fpage><lpage>1784</lpage><pub-id pub-id-type="doi">10.1172/JCI33940</pub-id><pub-id pub-id-type="pmid">18398511</pub-id>
</element-citation></ref><ref id="B40-vaccines-13-00193"><label>40.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>X.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Innate immune response to adenoviral vectors is mediated by both Toll-like receptor-dependent and -independent pathways</article-title><source>J. Virol.</source><year>2007</year><volume>81</volume><fpage>3170</fpage><lpage>3180</lpage><pub-id pub-id-type="doi">10.1128/JVI.02192-06</pub-id><pub-id pub-id-type="pmid">17229689</pub-id>
</element-citation></ref><ref id="B41-vaccines-13-00193"><label>41.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Chen</surname><given-names>G.</given-names></name>
<name><surname>Shaw</surname><given-names>M.H.</given-names></name>
<name><surname>Kim</surname><given-names>Y.G.</given-names></name>
<name><surname>Nu&#x000f1;ez</surname><given-names>G.</given-names></name>
</person-group><article-title>NOD-Like Receptors: Role in Innate Immunity and Inflammatory Disease</article-title><source>Annu. Rev. Pathol.</source><year>2009</year><volume>4</volume><fpage>365</fpage><lpage>398</lpage><pub-id pub-id-type="doi">10.1146/annurev.pathol.4.110807.092239</pub-id><pub-id pub-id-type="pmid">18928408</pub-id>
</element-citation></ref><ref id="B42-vaccines-13-00193"><label>42.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ting</surname><given-names>J.P.Y.</given-names></name>
<name><surname>Lovering</surname><given-names>R.C.</given-names></name>
<name><surname>Alnemri</surname><given-names>E.S.</given-names></name>
<name><surname>Bertin</surname><given-names>J.</given-names></name>
<name><surname>Boss</surname><given-names>J.M.</given-names></name>
<name><surname>Davis</surname><given-names>B.K.</given-names></name>
<name><surname>Flavell</surname><given-names>R.A.</given-names></name>
<name><surname>Girardin</surname><given-names>S.E.</given-names></name>
<name><surname>Godzik</surname><given-names>A.</given-names></name>
<name><surname>Harton</surname><given-names>J.A.</given-names></name>
<etal/>
</person-group><article-title>The NLR gene family: A standard nomenclature</article-title><source>Immunity</source><year>2008</year><volume>28</volume><fpage>285</fpage><lpage>287</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2008.02.005</pub-id><pub-id pub-id-type="pmid">18341998</pub-id>
</element-citation></ref><ref id="B43-vaccines-13-00193"><label>43.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Velloso</surname><given-names>F.J.</given-names></name>
<name><surname>Trombetta-Lima</surname><given-names>M.</given-names></name>
<name><surname>Anschau</surname><given-names>V.</given-names></name>
<name><surname>Sogayar</surname><given-names>M.C.</given-names></name>
<name><surname>Correa</surname><given-names>R.G.</given-names></name>
</person-group><article-title>NOD-like receptors: Major players (and targets) in the interface between innate immunity and cancer</article-title><source>Biosci. Rep.</source><year>2019</year><volume>39</volume><elocation-id>BSR20181709</elocation-id><pub-id pub-id-type="doi">10.1042/BSR20181709</pub-id><pub-id pub-id-type="pmid">30837326</pub-id>
</element-citation></ref><ref id="B44-vaccines-13-00193"><label>44.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Venuprasad</surname><given-names>K.</given-names></name>
<name><surname>Theiss</surname><given-names>A.L.</given-names></name>
</person-group><article-title>NLRP6 in host defense and intestinal inflammation</article-title><source>Cell Rep.</source><year>2021</year><volume>35</volume><fpage>109043</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2021.109043</pub-id><pub-id pub-id-type="pmid">33910012</pub-id>
</element-citation></ref><ref id="B45-vaccines-13-00193"><label>45.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Keestra-Gounder</surname><given-names>A.M.</given-names></name>
<name><surname>Tsolis</surname><given-names>R.M.</given-names></name>
</person-group><article-title>NOD1 and NOD2: Beyond Peptidoglycan Sensing</article-title><source>Trends Immunol.</source><year>2017</year><volume>38</volume><fpage>758</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1016/j.it.2017.07.004</pub-id><pub-id pub-id-type="pmid">28823510</pub-id>
</element-citation></ref><ref id="B46-vaccines-13-00193"><label>46.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sabbah</surname><given-names>A.</given-names></name>
<name><surname>Chang</surname><given-names>T.H.</given-names></name>
<name><surname>Harnack</surname><given-names>R.</given-names></name>
<name><surname>Frohlich</surname><given-names>V.</given-names></name>
<name><surname>Tominaga</surname><given-names>K.</given-names></name>
<name><surname>Dube</surname><given-names>P.H.</given-names></name>
<name><surname>Xiang</surname><given-names>Y.</given-names></name>
<name><surname>Bose</surname><given-names>S.</given-names></name>
</person-group><article-title>Activation of innate immune antiviral responses by Nod2</article-title><source>Nat. Immunol.</source><year>2009</year><volume>10</volume><fpage>1073</fpage><lpage>1080</lpage><pub-id pub-id-type="doi">10.1038/ni.1782</pub-id><pub-id pub-id-type="pmid">19701189</pub-id>
</element-citation></ref><ref id="B47-vaccines-13-00193"><label>47.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Mukherjee</surname><given-names>T.</given-names></name>
<name><surname>Hovingh</surname><given-names>E.S.</given-names></name>
<name><surname>Foerster</surname><given-names>E.G.</given-names></name>
<name><surname>Abdel-Nour</surname><given-names>M.</given-names></name>
<name><surname>Philpott</surname><given-names>D.J.</given-names></name>
<name><surname>Girardin</surname><given-names>S.E.</given-names></name>
</person-group><article-title>NOD1 and NOD2 in inflammation, immunity and disease</article-title><source>Arch. Biochem. Biophys.</source><year>2019</year><volume>670</volume><fpage>69</fpage><lpage>81</lpage><pub-id pub-id-type="doi">10.1016/j.abb.2018.12.022</pub-id><pub-id pub-id-type="pmid">30578751</pub-id>
</element-citation></ref><ref id="B48-vaccines-13-00193"><label>48.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>S.</given-names></name>
<name><surname>Ding</surname><given-names>S.</given-names></name>
<name><surname>Wang</surname><given-names>P.</given-names></name>
<name><surname>Wei</surname><given-names>Z.</given-names></name>
<name><surname>Pan</surname><given-names>W.</given-names></name>
<name><surname>Palm</surname><given-names>N.W.</given-names></name>
<name><surname>Yang</surname><given-names>Y.</given-names></name>
<name><surname>Yu</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>H.B.</given-names></name>
<name><surname>Wang</surname><given-names>G.</given-names></name>
<etal/>
</person-group><article-title>Nlrp9b inflammasome restricts rotavirus infection in intestinal epithelial cells</article-title><source>Nature</source><year>2017</year><volume>546</volume><fpage>667</fpage><lpage>670</lpage><pub-id pub-id-type="doi">10.1038/nature22967</pub-id><pub-id pub-id-type="pmid">28636595</pub-id>
</element-citation></ref><ref id="B49-vaccines-13-00193"><label>49.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Bruns</surname><given-names>A.M.</given-names></name>
<name><surname>Horvath</surname><given-names>C.M.</given-names></name>
</person-group><article-title>Antiviral RNA recognition and assembly by RLR family innate immune sensors</article-title><source>Cytokine Growth Factor Rev.</source><year>2014</year><volume>25</volume><fpage>507</fpage><lpage>512</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2014.07.006</pub-id><pub-id pub-id-type="pmid">25081315</pub-id>
</element-citation></ref><ref id="B50-vaccines-13-00193"><label>50.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Solstad</surname><given-names>A.</given-names></name>
<name><surname>Hogaboam</surname><given-names>O.</given-names></name>
<name><surname>Forero</surname><given-names>A.</given-names></name>
<name><surname>Hemann</surname><given-names>E.A.</given-names></name>
</person-group><article-title>RIG-I-like Receptor Regulation of Immune Cell Function and Therapeutic Implications</article-title><source>J. Immunol.</source><year>2022</year><volume>209</volume><fpage>845</fpage><lpage>854</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.2200395</pub-id><pub-id pub-id-type="pmid">36130131</pub-id>
</element-citation></ref><ref id="B51-vaccines-13-00193"><label>51.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moran</surname><given-names>E.A.</given-names></name>
<name><surname>Ross</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Insights into Sensing of Murine Retroviruses</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>836</elocation-id><pub-id pub-id-type="doi">10.3390/v12080836</pub-id><pub-id pub-id-type="pmid">32751803</pub-id>
</element-citation></ref><ref id="B52-vaccines-13-00193"><label>52.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Itell</surname><given-names>H.L.</given-names></name>
<name><surname>Humes</surname><given-names>D.</given-names></name>
<name><surname>Overbaugh</surname><given-names>J.</given-names></name>
</person-group><article-title>Several cell-intrinsic effectors drive type I interferon-mediated restriction of HIV-1 in primary CD4+ T cells</article-title><source>Cell Rep.</source><year>2023</year><volume>42</volume><fpage>112556</fpage><pub-id pub-id-type="doi">10.1016/j.celrep.2023.112556</pub-id><pub-id pub-id-type="pmid">37227817</pub-id>
</element-citation></ref><ref id="B53-vaccines-13-00193"><label>53.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hotter</surname><given-names>D.</given-names></name>
<name><surname>Bosso</surname><given-names>M.</given-names></name>
<name><surname>J&#x000f8;nsson</surname><given-names>K.L.</given-names></name>
<name><surname>Krapp</surname><given-names>C.</given-names></name>
<name><surname>St&#x000fc;rzel</surname><given-names>C.M.</given-names></name>
<name><surname>Das</surname><given-names>A.</given-names></name>
<name><surname>Littwitz-Salomon</surname><given-names>E.</given-names></name>
<name><surname>Berkhout</surname><given-names>B.</given-names></name>
<name><surname>Russ</surname><given-names>A.</given-names></name>
<name><surname>Wittmann</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>IFI16 targets the transcription factor Sp1 to suppress HIV-1 transcription and latency reactivation</article-title><source>Cell Host Microbe</source><year>2019</year><volume>25</volume><fpage>858</fpage><lpage>872.e13</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2019.05.002</pub-id><pub-id pub-id-type="pmid">31175045</pub-id>
</element-citation></ref><ref id="B54-vaccines-13-00193"><label>54.</label><element-citation publication-type="book"><person-group person-group-type="author">
<name><surname>Coffin</surname><given-names>J.M.</given-names></name>
<name><surname>Hughes</surname><given-names>S.H.</given-names></name>
<name><surname>Varmus</surname><given-names>H.E.</given-names></name>
</person-group><source>Retroviruses</source><publisher-name>Cold Spring Harbor Laboratory Press</publisher-name><publisher-loc>Long Island, NY, USA</publisher-loc><year>1997</year><comment>ISBN-10: 0-87969-571-4</comment></element-citation></ref><ref id="B55-vaccines-13-00193"><label>55.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Rassa</surname><given-names>J.C.</given-names></name>
<name><surname>Meyers</surname><given-names>J.L.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Kudaravalli</surname><given-names>R.</given-names></name>
<name><surname>Ross</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Murine retroviruses activate B cells via interaction with toll-like receptor 4</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2002</year><volume>99</volume><fpage>2281</fpage><lpage>2286</lpage><pub-id pub-id-type="doi">10.1073/pnas.042355399</pub-id><pub-id pub-id-type="pmid">11854525</pub-id>
</element-citation></ref><ref id="B56-vaccines-13-00193"><label>56.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Persaud</surname><given-names>A.T.</given-names></name>
<name><surname>Khela</surname><given-names>J.</given-names></name>
<name><surname>Fernandes</surname><given-names>C.</given-names></name>
<name><surname>Chaphekar</surname><given-names>D.</given-names></name>
<name><surname>Burnie</surname><given-names>J.</given-names></name>
<name><surname>Tang</surname><given-names>V.A.</given-names></name>
<name><surname>Colpitts</surname><given-names>C.C.</given-names></name>
<name><surname>Guzzo</surname><given-names>C.</given-names></name>
</person-group><article-title>Virion-incorporated CD14 enables HIV-1 to bind LPS and initiate TLR4 signaling in immune cells</article-title><source>J. Virol.</source><year>2024</year><volume>98</volume><fpage>e0036324</fpage><pub-id pub-id-type="doi">10.1128/jvi.00363-24</pub-id><pub-id pub-id-type="pmid">38661384</pub-id>
</element-citation></ref><ref id="B57-vaccines-13-00193"><label>57.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wilks</surname><given-names>J.</given-names></name>
<name><surname>Lien</surname><given-names>E.</given-names></name>
<name><surname>Jacobson</surname><given-names>A.N.</given-names></name>
<name><surname>Fischbach</surname><given-names>M.A.</given-names></name>
<name><surname>Qureshi</surname><given-names>N.</given-names></name>
<name><surname>Chervonsky</surname><given-names>A.V.</given-names></name>
<name><surname>Golovkina</surname><given-names>T.V.</given-names></name>
</person-group><article-title>Mammalian lipopolysaccharide receptors incorporated into the retroviral envelope augment virus transmission</article-title><source>Cell Host Microbe</source><year>2015</year><volume>18</volume><fpage>456</fpage><lpage>462</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.09.005</pub-id><pub-id pub-id-type="pmid">26468748</pub-id>
</element-citation></ref><ref id="B58-vaccines-13-00193"><label>58.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Du</surname><given-names>F.</given-names></name>
<name><surname>Chen</surname><given-names>X.</given-names></name>
<name><surname>Chen</surname><given-names>Z.J.</given-names></name>
</person-group><article-title>Cyclic GMP-AMP Synthase Is a Cytosolic DNA Sensor That Activates the Type I Interferon Pathway</article-title><source>Science</source><year>2013</year><volume>339</volume><fpage>786</fpage><lpage>791</lpage><pub-id pub-id-type="doi">10.1126/science.1232458</pub-id><pub-id pub-id-type="pmid">23258413</pub-id>
</element-citation></ref><ref id="B59-vaccines-13-00193"><label>59.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tan</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>J.</given-names></name>
<name><surname>Chen</surname><given-names>Z.J.</given-names></name>
</person-group><article-title>Detection of Microbial Infections Through Innate Immune Sensing of Nucleic Acids</article-title><source>Annu. Rev. Microbiol.</source><year>2018</year><volume>72</volume><fpage>447</fpage><lpage>478</lpage><pub-id pub-id-type="doi">10.1146/annurev-micro-102215-095605</pub-id><pub-id pub-id-type="pmid">30200854</pub-id>
</element-citation></ref><ref id="B60-vaccines-13-00193"><label>60.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Xiao</surname><given-names>T.S.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>K.A.</given-names></name>
</person-group><article-title>The cGAS-STING pathway for DNA sensing</article-title><source>Mol. Cell</source><year>2013</year><volume>51</volume><fpage>135</fpage><lpage>139</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2013.07.004</pub-id><pub-id pub-id-type="pmid">23870141</pub-id>
</element-citation></ref><ref id="B61-vaccines-13-00193"><label>61.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cai</surname><given-names>X.</given-names></name>
<name><surname>Chiu</surname><given-names>Y.H.</given-names></name>
<name><surname>Chen</surname><given-names>Z.J.</given-names></name>
</person-group><article-title>The cGAS-cGAMP-STING pathway of cytosolic DNA sensing and signaling</article-title><source>Mol. Cell</source><year>2014</year><volume>54</volume><fpage>289</fpage><lpage>296</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2014.03.040</pub-id><pub-id pub-id-type="pmid">24766893</pub-id>
</element-citation></ref><ref id="B62-vaccines-13-00193"><label>62.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Moriyama</surname><given-names>M.</given-names></name>
<name><surname>Koshiba</surname><given-names>T.</given-names></name>
<name><surname>Ichinohe</surname><given-names>T.</given-names></name>
</person-group><article-title>Influenza A virus M2 protein triggers mitochondrial DNA-mediated antiviral immune responses</article-title><source>Nat. Commun.</source><year>2019</year><volume>10</volume><fpage>4624</fpage><pub-id pub-id-type="doi">10.1038/s41467-019-12632-5</pub-id><pub-id pub-id-type="pmid">31604929</pub-id>
</element-citation></ref><ref id="B63-vaccines-13-00193"><label>63.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhu</surname><given-names>T.</given-names></name>
<name><surname>Fernandez-Sesma</surname><given-names>A.</given-names></name>
</person-group><article-title>Innate Immune DNA Sensing of Flaviviruses</article-title><source>Viruses</source><year>2020</year><volume>12</volume><elocation-id>979</elocation-id><pub-id pub-id-type="doi">10.3390/v12090979</pub-id><pub-id pub-id-type="pmid">32899347</pub-id>
</element-citation></ref><ref id="B64-vaccines-13-00193"><label>64.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Barber</surname><given-names>G.N.</given-names></name>
</person-group><article-title>STING: Infection, inflammation and cancer</article-title><source>Nat. Rev. Immunol.</source><year>2015</year><volume>15</volume><fpage>760</fpage><lpage>770</lpage><pub-id pub-id-type="doi">10.1038/nri3921</pub-id><pub-id pub-id-type="pmid">26603901</pub-id>
</element-citation></ref><ref id="B65-vaccines-13-00193"><label>65.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Brunette</surname><given-names>R.L.</given-names></name>
<name><surname>Young</surname><given-names>J.M.</given-names></name>
<name><surname>Whitley</surname><given-names>D.G.</given-names></name>
<name><surname>Brodsky</surname><given-names>I.E.</given-names></name>
<name><surname>Malik</surname><given-names>H.S.</given-names></name>
<name><surname>Stetson</surname><given-names>D.B.</given-names></name>
</person-group><article-title>Extensive evolutionary and functional diversity among mammalian AIM2-like receptors</article-title><source>J. Exp. Med.</source><year>2012</year><volume>209</volume><fpage>1969</fpage><lpage>1983</lpage><pub-id pub-id-type="doi">10.1084/jem.20121960</pub-id><pub-id pub-id-type="pmid">23045604</pub-id>
</element-citation></ref><ref id="B66-vaccines-13-00193"><label>66.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Nakaya</surname><given-names>Y.</given-names></name>
<name><surname>Lilue</surname><given-names>J.</given-names></name>
<name><surname>Stavrou</surname><given-names>S.</given-names></name>
<name><surname>Moran</surname><given-names>E.</given-names></name>
<name><surname>Ross</surname><given-names>S.R.</given-names></name>
</person-group><article-title>AIM2-like receptors positively and negatively regulate the interferon response induced by cytosolic DNA</article-title><source>MBio</source><year>2017</year><volume>8</volume><elocation-id>e00944-17</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00944-17</pub-id><pub-id pub-id-type="pmid">28679751</pub-id>
</element-citation></ref><ref id="B67-vaccines-13-00193"><label>67.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Cagliani</surname><given-names>R.</given-names></name>
<name><surname>Forni</surname><given-names>D.</given-names></name>
<name><surname>Biasin</surname><given-names>M.</given-names></name>
<name><surname>Comabella</surname><given-names>M.</given-names></name>
<name><surname>Guerini</surname><given-names>F.R.</given-names></name>
<name><surname>Riva</surname><given-names>S.</given-names></name>
<name><surname>Pozzoli</surname><given-names>U.</given-names></name>
<name><surname>Agliardi</surname><given-names>C.</given-names></name>
<name><surname>Caputo</surname><given-names>D.</given-names></name>
<name><surname>Malhotra</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Ancient and recent selective pressures shaped genetic diversity at AIM2-like nucleic acid sensors</article-title><source>Genome Biol. Evol.</source><year>2014</year><volume>6</volume><fpage>830</fpage><lpage>845</lpage><pub-id pub-id-type="doi">10.1093/gbe/evu066</pub-id><pub-id pub-id-type="pmid">24682156</pub-id>
</element-citation></ref><ref id="B68-vaccines-13-00193"><label>68.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stavrou</surname><given-names>S.</given-names></name>
<name><surname>Blouch</surname><given-names>K.</given-names></name>
<name><surname>Kotla</surname><given-names>S.</given-names></name>
<name><surname>Bass</surname><given-names>A.</given-names></name>
<name><surname>Ross</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Nucleic acid recognition orchestrates the anti-viral response to retroviruses</article-title><source>Cell Host Microbe</source><year>2015</year><volume>17</volume><fpage>478</fpage><lpage>488</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2015.02.021</pub-id><pub-id pub-id-type="pmid">25816774</pub-id>
</element-citation></ref><ref id="B69-vaccines-13-00193"><label>69.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Unterholzner</surname><given-names>L.</given-names></name>
<name><surname>Keating</surname><given-names>S.E.</given-names></name>
<name><surname>Baran</surname><given-names>M.</given-names></name>
<name><surname>Horan</surname><given-names>K.A.</given-names></name>
<name><surname>Jensen</surname><given-names>S.B.</given-names></name>
<name><surname>Sharma</surname><given-names>S.</given-names></name>
<name><surname>Sirois</surname><given-names>C.M.</given-names></name>
<name><surname>Jin</surname><given-names>T.</given-names></name>
<name><surname>Latz</surname><given-names>E.</given-names></name>
<name><surname>Xiao</surname><given-names>T.S.</given-names></name>
<etal/>
</person-group><article-title>IFI16 is an innate immune sensor for intracellular DNA</article-title><source>Nat. Immunol.</source><year>2010</year><volume>11</volume><fpage>997</fpage><lpage>1004</lpage><pub-id pub-id-type="doi">10.1038/ni.1932</pub-id><pub-id pub-id-type="pmid">20890285</pub-id>
</element-citation></ref><ref id="B70-vaccines-13-00193"><label>70.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hornung</surname><given-names>V.</given-names></name>
<name><surname>Ablasser</surname><given-names>A.</given-names></name>
<name><surname>Charrel-Dennis</surname><given-names>M.</given-names></name>
<name><surname>Bauernfeind</surname><given-names>F.</given-names></name>
<name><surname>Horvath</surname><given-names>G.</given-names></name>
<name><surname>Caffrey</surname><given-names>D.R.</given-names></name>
<name><surname>Latz</surname><given-names>E.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>K.A.</given-names></name>
</person-group><article-title>AIM2 recognizes cytosolic dsDNA and forms a caspase1-activating inflammasome with ASC</article-title><source>Nature</source><year>2009</year><volume>458</volume><fpage>514</fpage><lpage>518</lpage><pub-id pub-id-type="doi">10.1038/nature07725</pub-id><pub-id pub-id-type="pmid">19158675</pub-id>
</element-citation></ref><ref id="B71-vaccines-13-00193"><label>71.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jin</surname><given-names>T.</given-names></name>
<name><surname>Perry</surname><given-names>A.</given-names></name>
<name><surname>Jiang</surname><given-names>J.</given-names></name>
<name><surname>Smith</surname><given-names>P.</given-names></name>
<name><surname>Curry</surname><given-names>J.A.</given-names></name>
<name><surname>Unterholzner</surname><given-names>L.</given-names></name>
<name><surname>Jiang</surname><given-names>Z.</given-names></name>
<name><surname>Horvath</surname><given-names>G.</given-names></name>
<name><surname>Rathinam</surname><given-names>V.A.</given-names></name>
<name><surname>Johnstone</surname><given-names>R.W.</given-names></name>
<etal/>
</person-group><article-title>Structures of the HIN domain: DNA complexes reveal ligand binding and activation mechanisms of the AIM2 inflammasome and IFI16 receptor</article-title><source>Immunity</source><year>2012</year><volume>36</volume><fpage>561</fpage><lpage>571</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2012.02.014</pub-id><pub-id pub-id-type="pmid">22483801</pub-id>
</element-citation></ref><ref id="B72-vaccines-13-00193"><label>72.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Erdemci-Evin</surname><given-names>S.</given-names></name>
<name><surname>Bosso</surname><given-names>M.</given-names></name>
<name><surname>Krchlikova</surname><given-names>V.</given-names></name>
<name><surname>Bayer</surname><given-names>W.</given-names></name>
<name><surname>Regensburger</surname><given-names>K.</given-names></name>
<name><surname>Mayer</surname><given-names>M.</given-names></name>
<name><surname>Dittmer</surname><given-names>U.</given-names></name>
<name><surname>Sauter</surname><given-names>D.</given-names></name>
<name><surname>Kmiec</surname><given-names>D.</given-names></name>
<name><surname>Kirchhoff</surname><given-names>F.</given-names></name>
</person-group><article-title>A Variety of Mouse PYHIN Proteins Restrict Murine and Human Retroviruses</article-title><source>Viruses</source><year>2024</year><volume>16</volume><elocation-id>493</elocation-id><pub-id pub-id-type="doi">10.3390/v16040493</pub-id><pub-id pub-id-type="pmid">38675836</pub-id>
</element-citation></ref><ref id="B73-vaccines-13-00193"><label>73.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Jakobsen</surname><given-names>M.R.</given-names></name>
<name><surname>Bak</surname><given-names>R.O.</given-names></name>
<name><surname>Andersen</surname><given-names>A.</given-names></name>
<name><surname>Berg</surname><given-names>R.K.</given-names></name>
<name><surname>Jensen</surname><given-names>S.B.</given-names></name>
<name><surname>Tengchuan</surname><given-names>J.</given-names></name>
<name><surname>Jin</surname><given-names>T.</given-names></name>
<name><surname>Laustsen</surname><given-names>A.</given-names></name>
<name><surname>Hansen</surname><given-names>K.</given-names></name>
<name><surname>Ostergaard</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>IFI16 senses DNA forms of the lentiviral replication cycle and controls HIV-1 replication</article-title><source>Proc. Natl. Acad. Sci. USA</source><year>2013</year><volume>110</volume><elocation-id>E4571-80</elocation-id><pub-id pub-id-type="doi">10.1073/pnas.1311669110</pub-id><pub-id pub-id-type="pmid">24154727</pub-id>
</element-citation></ref><ref id="B74-vaccines-13-00193"><label>74.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gao</surname><given-names>D.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Y.T.</given-names></name>
<name><surname>Du</surname><given-names>F.</given-names></name>
<name><surname>Aroh</surname><given-names>C.</given-names></name>
<name><surname>Yan</surname><given-names>N.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>Z.J.</given-names></name>
</person-group><article-title>Cyclic GMP-AMP synthase is an innate immune sensor of HIV and other retroviruses</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>903</fpage><lpage>906</lpage><pub-id pub-id-type="doi">10.1126/science.1240933</pub-id><pub-id pub-id-type="pmid">23929945</pub-id>
</element-citation></ref><ref id="B75-vaccines-13-00193"><label>75.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Knipe</surname><given-names>D.M.</given-names></name>
</person-group><article-title>Nuclear sensing of viral DNA, epigenetic regulation of herpes simplex virus infection, and innate immunity</article-title><source>Virology</source><year>2015</year><volume>479&#x02013;480</volume><fpage>153</fpage><lpage>159</lpage><pub-id pub-id-type="doi">10.1016/j.virol.2015.02.009</pub-id><pub-id pub-id-type="pmid">25742715</pub-id>
</element-citation></ref><ref id="B76-vaccines-13-00193"><label>76.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Amurri</surname><given-names>L.</given-names></name>
<name><surname>Dumont</surname><given-names>C.</given-names></name>
<name><surname>Pelissier</surname><given-names>R.</given-names></name>
<name><surname>Reynard</surname><given-names>O.</given-names></name>
<name><surname>Mathieu</surname><given-names>C.</given-names></name>
<name><surname>Spanier</surname><given-names>J.</given-names></name>
<name><surname>P&#x000e1;lyi</surname><given-names>B.</given-names></name>
<name><surname>D&#x000e9;ri</surname><given-names>D.</given-names></name>
<name><surname>Karkowski</surname><given-names>L.</given-names></name>
<name><surname>Gonzalez</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>Multifaceted activation of STING axis upon Nipah and measles virus-induced syncytia formation</article-title><source>PLoS Pathog.</source><year>2024</year><volume>20</volume><elocation-id>e1012569</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1012569</pub-id><pub-id pub-id-type="pmid">39283943</pub-id>
</element-citation></ref><ref id="B77-vaccines-13-00193"><label>77.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stunnenberg</surname><given-names>M.</given-names></name>
<name><surname>Geijtenbeek</surname><given-names>T.B.H.</given-names></name>
<name><surname>Gringhuis</surname><given-names>S.I.</given-names></name>
</person-group><article-title>DDX3 in HIV-1 infection and sensing: A paradox</article-title><source>Cytokine Growth Factor Rev.</source><year>2018</year><volume>40</volume><fpage>32</fpage><lpage>39</lpage><pub-id pub-id-type="doi">10.1016/j.cytogfr.2018.03.001</pub-id><pub-id pub-id-type="pmid">29580812</pub-id>
</element-citation></ref><ref id="B78-vaccines-13-00193"><label>78.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Stavrou</surname><given-names>S.</given-names></name>
<name><surname>Aguilera</surname><given-names>A.N.</given-names></name>
<name><surname>Blouch</surname><given-names>K.</given-names></name>
<name><surname>Ross</surname><given-names>S.R.</given-names></name>
</person-group><article-title>DDX41 Recognizes RNA/DNA Retroviral Reverse Transcripts and Is Critical for In Vivo Control of Murine Leukemia Virus Infection</article-title><source>MBio</source><year>2018</year><volume>9</volume><elocation-id>e00923-18</elocation-id><pub-id pub-id-type="doi">10.1128/mBio.00923-18</pub-id><pub-id pub-id-type="pmid">29871919</pub-id>
</element-citation></ref><ref id="B79-vaccines-13-00193"><label>79.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ma</surname><given-names>J.</given-names></name>
<name><surname>Ross</surname><given-names>S.R.</given-names></name>
</person-group><article-title>Multifunctional role of DEAD-box helicase 41 in innate immunity, hematopoiesis and disease</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1451705</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1451705</pub-id><pub-id pub-id-type="pmid">39185415</pub-id>
</element-citation></ref><ref id="B80-vaccines-13-00193"><label>80.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Balka</surname><given-names>K.R.</given-names></name>
<name><surname>Venkatraman</surname><given-names>R.</given-names></name>
<name><surname>Saunders</surname><given-names>T.L.</given-names></name>
<name><surname>Shoppee</surname><given-names>A.</given-names></name>
<name><surname>Pang</surname><given-names>E.S.</given-names></name>
<name><surname>Magill</surname><given-names>Z.</given-names></name>
<name><surname>Homman-Ludiye</surname><given-names>J.</given-names></name>
<name><surname>Huang</surname><given-names>C.</given-names></name>
<name><surname>Lane</surname><given-names>R.M.</given-names></name>
<name><surname>York</surname><given-names>H.M.</given-names></name>
<etal/>
</person-group><article-title>Termination of STING responses is mediated via ESCRT-dependent degradation</article-title><source>EMBO J.</source><year>2023</year><volume>42</volume><fpage>e112712</fpage><pub-id pub-id-type="doi">10.15252/embj.2022112712</pub-id><pub-id pub-id-type="pmid">37139896</pub-id>
</element-citation></ref><ref id="B81-vaccines-13-00193"><label>81.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gentili</surname><given-names>M.</given-names></name>
<name><surname>Liu</surname><given-names>B.</given-names></name>
<name><surname>Papanastasiou</surname><given-names>M.</given-names></name>
<name><surname>Dele-Oni</surname><given-names>D.</given-names></name>
<name><surname>Schwartz</surname><given-names>M.A.</given-names></name>
<name><surname>Carlson</surname><given-names>R.J.</given-names></name>
<name><surname>Al&#x02019;Khafaji</surname><given-names>A.M.</given-names></name>
<name><surname>Krug</surname><given-names>K.</given-names></name>
<name><surname>Brown</surname><given-names>A.</given-names></name>
<name><surname>Doench</surname><given-names>J.G.</given-names></name>
<etal/>
</person-group><article-title>ESCRT-dependent STING degradation inhibits steady-state and cGAMP-induced signaling</article-title><source>Nat. Commun.</source><year>2023</year><volume>14</volume><fpage>611</fpage><pub-id pub-id-type="doi">10.1038/s41467-023-36132-9</pub-id><pub-id pub-id-type="pmid">36739287</pub-id>
</element-citation></ref><ref id="B82-vaccines-13-00193"><label>82.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuchitsu</surname><given-names>Y.</given-names></name>
<name><surname>Mukai</surname><given-names>K.</given-names></name>
<name><surname>Uematsu</surname><given-names>R.</given-names></name>
<name><surname>Takaada</surname><given-names>Y.</given-names></name>
<name><surname>Shinojima</surname><given-names>A.</given-names></name>
<name><surname>Shindo</surname><given-names>R.</given-names></name>
<name><surname>Shoji</surname><given-names>T.</given-names></name>
<name><surname>Hamano</surname><given-names>S.</given-names></name>
<name><surname>Ogawa</surname><given-names>E.</given-names></name>
<name><surname>Sato</surname><given-names>R.</given-names></name>
<etal/>
</person-group><article-title>STING signalling is terminated through ESCRT-dependent microautophagy of vesicles originating from recycling endosomes</article-title><source>Nat. Cell Biol.</source><year>2023</year><volume>25</volume><fpage>453</fpage><lpage>466</lpage><pub-id pub-id-type="doi">10.1038/s41556-023-01098-9</pub-id><pub-id pub-id-type="pmid">36918692</pub-id>
</element-citation></ref><ref id="B83-vaccines-13-00193"><label>83.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>K.</given-names></name>
<name><surname>Huang</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>X.</given-names></name>
<name><surname>Zhao</surname><given-names>Z.</given-names></name>
<name><surname>Hong</surname><given-names>C.</given-names></name>
<name><surname>Sun</surname><given-names>Z.</given-names></name>
<name><surname>Deng</surname><given-names>B.</given-names></name>
<name><surname>Li</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>J.</given-names></name>
<name><surname>Wangm</surname><given-names>S.</given-names></name>
</person-group><article-title>The cGAS-STING pathway in viral infections: A promising link between inflammation, oxidative stress and autophagy</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1352479</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1352479</pub-id><pub-id pub-id-type="pmid">38426093</pub-id>
</element-citation></ref><ref id="B84-vaccines-13-00193"><label>84.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhao</surname><given-names>L.</given-names></name>
<name><surname>Yuan</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Geng</surname><given-names>Y.</given-names></name>
<name><surname>Yun</surname><given-names>H.</given-names></name>
<name><surname>Zheng</surname><given-names>W.</given-names></name>
<name><surname>Yuan</surname><given-names>Y.</given-names></name>
<name><surname>Lv</surname><given-names>P.</given-names></name>
<name><surname>Hou</surname><given-names>C.</given-names></name>
<name><surname>Zhang</surname><given-names>H.</given-names></name>
<etal/>
</person-group><article-title>HBV confers innate immune evasion through triggering HAT1/acetylation of H4K5/H4K12/miR-181a-5p or KPNA2/cGAS-STING/IFN-I signaling</article-title><source>J. Med. Virol.</source><year>2023</year><volume>95</volume><fpage>e28966</fpage><pub-id pub-id-type="doi">10.1002/jmv.28966</pub-id><pub-id pub-id-type="pmid">37466313</pub-id>
</element-citation></ref><ref id="B85-vaccines-13-00193"><label>85.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lio</surname><given-names>C.W.</given-names></name>
<name><surname>McDonald</surname><given-names>B.</given-names></name>
<name><surname>Takahashi</surname><given-names>M.</given-names></name>
<name><surname>Dhanwani</surname><given-names>R.</given-names></name>
<name><surname>Sharma</surname><given-names>N.</given-names></name>
<name><surname>Huang</surname><given-names>J.</given-names></name>
<name><surname>Pham</surname><given-names>E.</given-names></name>
<name><surname>Benedict</surname><given-names>C.A.</given-names></name>
<name><surname>Sharmaet</surname><given-names>S.</given-names></name>
</person-group><article-title>cGAS-STING signaling regulates initial innate control of cytomegalovirus infection</article-title><source>J. Virol.</source><year>2016</year><volume>90</volume><fpage>7789</fpage><lpage>7797</lpage><pub-id pub-id-type="doi">10.1128/JVI.01040-16</pub-id><pub-id pub-id-type="pmid">27334590</pub-id>
</element-citation></ref><ref id="B86-vaccines-13-00193"><label>86.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Reinert</surname><given-names>L.S.</given-names></name>
<name><surname>Lopu&#x00161;n&#x000e1;</surname><given-names>K.</given-names></name>
<name><surname>Winther</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>C.</given-names></name>
<name><surname>Thomsen</surname><given-names>M.K.</given-names></name>
<name><surname>Nandakumar</surname><given-names>R.</given-names></name>
<name><surname>Mogensen</surname><given-names>T.H.</given-names></name>
<name><surname>Meyer</surname><given-names>M.</given-names></name>
<name><surname>V&#x000e6;gter</surname><given-names>C.</given-names></name>
<name><surname>Nyengaard</surname><given-names>J.R.</given-names></name>
<etal/>
</person-group><article-title>Sensing of HSV-1 by the cGAS&#x02013;STING pathway in microglia orchestrates antiviral defence in the CNS</article-title><source>Nat. Commun.</source><year>2016</year><volume>7</volume><fpage>13348</fpage><pub-id pub-id-type="doi">10.1038/ncomms13348</pub-id><pub-id pub-id-type="pmid">27830700</pub-id>
</element-citation></ref><ref id="B87-vaccines-13-00193"><label>87.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Christensen</surname><given-names>M.H.</given-names></name>
<name><surname>Jensen</surname><given-names>S.B.</given-names></name>
<name><surname>Miettinen</surname><given-names>J.J.</given-names></name>
<name><surname>Luecke</surname><given-names>S.</given-names></name>
<name><surname>Prabakaran</surname><given-names>T.</given-names></name>
<name><surname>Reinert</surname><given-names>L.S.</given-names></name>
<name><surname>Mettenleiter</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>Z.J.</given-names></name>
<name><surname>Knipe</surname><given-names>D.M.</given-names></name>
<name><surname>Sandri-Goldin</surname><given-names>R.M.</given-names></name>
<etal/>
</person-group><article-title>HSV-1 ICP27 targets the TBK1-activated STING signalsome to inhibit virus-induced type I IFN expression</article-title><source>EMBO J.</source><year>2016</year><volume>35</volume><fpage>1385</fpage><lpage>1399</lpage><pub-id pub-id-type="doi">10.15252/embj.201593458</pub-id><pub-id pub-id-type="pmid">27234299</pub-id>
</element-citation></ref><ref id="B88-vaccines-13-00193"><label>88.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Fu</surname><given-names>Y.Z.</given-names></name>
<name><surname>Su</surname><given-names>S.</given-names></name>
<name><surname>Gao</surname><given-names>Y.Q.</given-names></name>
<name><surname>Wang</surname><given-names>P.P.</given-names></name>
<name><surname>Huang</surname><given-names>Z.F.</given-names></name>
<name><surname>Hu</surname><given-names>M.M.</given-names></name>
<name><surname>Luo</surname><given-names>W.W.</given-names></name>
<name><surname>Li</surname><given-names>S.</given-names></name>
<name><surname>Luo</surname><given-names>M.H.</given-names></name>
<name><surname>Wang</surname><given-names>Y.Y.</given-names></name>
<etal/>
</person-group><article-title>Human Cytomegalovirus Tegument Protein UL82 Inhibits STING-Mediated Signaling to Evade Antiviral Immunity</article-title><source>Cell Host Microbe</source><year>2017</year><volume>21</volume><fpage>231</fpage><lpage>243</lpage><pub-id pub-id-type="doi">10.1016/j.chom.2017.01.001</pub-id><pub-id pub-id-type="pmid">28132838</pub-id>
</element-citation></ref><ref id="B89-vaccines-13-00193"><label>89.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lui</surname><given-names>W.Y.</given-names></name>
<name><surname>Bharti</surname><given-names>A.</given-names></name>
<name><surname>Wong</surname><given-names>N.H.M.</given-names></name>
<name><surname>Jangra</surname><given-names>S.</given-names></name>
<name><surname>Botelho</surname><given-names>M.G.</given-names></name>
<name><surname>Yuen</surname><given-names>K.S.</given-names></name>
<name><surname>Jin</surname><given-names>D.Y.</given-names></name>
</person-group><article-title>Suppression of cGAS- and RIG-I-mediated innate immune signaling by Epstein-Barr virus deubiquitinase BPLF1</article-title><source>PLoS Pathog.</source><year>2023</year><volume>19</volume><elocation-id>e1011186</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1011186</pub-id><pub-id pub-id-type="pmid">36802409</pub-id>
</element-citation></ref><ref id="B90-vaccines-13-00193"><label>90.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kong</surname><given-names>Z.</given-names></name>
<name><surname>Yin</surname><given-names>H.</given-names></name>
<name><surname>Wang</surname><given-names>F.</given-names></name>
<name><surname>Liu</surname><given-names>Z.</given-names></name>
<name><surname>Luan</surname><given-names>X.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Liu</surname><given-names>W.</given-names></name>
<name><surname>Shang</surname><given-names>Y.</given-names></name>
</person-group><article-title>Pseudorabies virus tegument protein UL13 recruits RNF5 to inhibit STING-mediated antiviral immunity</article-title><source>PLoS Pathog.</source><year>2022</year><volume>18</volume><elocation-id>e1010544</elocation-id><pub-id pub-id-type="doi">10.1371/journal.ppat.1010544</pub-id><pub-id pub-id-type="pmid">35584187</pub-id>
</element-citation></ref><ref id="B91-vaccines-13-00193"><label>91.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Panchanathan</surname><given-names>R.</given-names></name>
<name><surname>Liu</surname><given-names>H.</given-names></name>
<name><surname>Xin</surname><given-names>D.</given-names></name>
<name><surname>Choubey</surname><given-names>D.</given-names></name>
</person-group><article-title>Identification of a negative feedback loop between cyclic di-GMP-induced levels of IFI16 and p202 cytosolic DNA sensors and STING</article-title><source>Innate Immun.</source><year>2014</year><volume>20</volume><fpage>751</fpage><lpage>759</lpage><pub-id pub-id-type="doi">10.1177/1753425913507097</pub-id><pub-id pub-id-type="pmid">24131791</pub-id>
</element-citation></ref><ref id="B92-vaccines-13-00193"><label>92.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Coffman</surname><given-names>R.L.</given-names></name>
<name><surname>Sher</surname><given-names>A.</given-names></name>
<name><surname>Seder</surname><given-names>R.A.</given-names></name>
</person-group><article-title>Vaccine adjuvants: Putting innate immunity to work</article-title><source>Immunity</source><year>2010</year><volume>33</volume><fpage>492</fpage><lpage>503</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2010.10.002</pub-id><pub-id pub-id-type="pmid">21029960</pub-id>
</element-citation></ref><ref id="B93-vaccines-13-00193"><label>93.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Pulendran</surname><given-names>B.</given-names></name>
<name><surname>Ahmed</surname><given-names>R.</given-names></name>
</person-group><article-title>Immunological mechanisms of vaccination</article-title><source>Nature Immunol.</source><year>2011</year><volume>12</volume><fpage>509</fpage><lpage>517</lpage><pub-id pub-id-type="doi">10.1038/ni.2039</pub-id><pub-id pub-id-type="pmid">21739679</pub-id>
</element-citation></ref><ref id="B94-vaccines-13-00193"><label>94.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Desmet</surname><given-names>C.J.</given-names></name>
<name><surname>Ishii</surname><given-names>K.J.</given-names></name>
</person-group><article-title>Nucleic acid sensing at the interface between innate and adaptive immunity in vaccination</article-title><source>Nat. Rev. Immunol.</source><year>2012</year><volume>12</volume><fpage>479</fpage><lpage>491</lpage><pub-id pub-id-type="doi">10.1038/nri3247</pub-id><pub-id pub-id-type="pmid">22728526</pub-id>
</element-citation></ref><ref id="B95-vaccines-13-00193"><label>95.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Iwasaki</surname><given-names>A.</given-names></name>
<name><surname>Medzhitov</surname><given-names>R.</given-names></name>
</person-group><article-title>Regulation of adaptive immunity by the innate immune system</article-title><source>Science</source><year>2010</year><volume>327</volume><fpage>291</fpage><lpage>295</lpage><pub-id pub-id-type="doi">10.1126/science.1183021</pub-id><pub-id pub-id-type="pmid">20075244</pub-id>
</element-citation></ref><ref id="B96-vaccines-13-00193"><label>96.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kuo</surname><given-names>T.Y.</given-names></name>
<name><surname>Lin</surname><given-names>M.Y.</given-names></name>
<name><surname>Coffman</surname><given-names>R.L.</given-names></name>
<name><surname>Campbell</surname><given-names>J.D.</given-names></name>
<name><surname>Traquina</surname><given-names>P.</given-names></name>
<name><surname>Lin</surname><given-names>Y.J.</given-names></name>
<name><surname>Liu</surname><given-names>L.T.C.</given-names></name>
<name><surname>Cheng</surname><given-names>J.</given-names></name>
<name><surname>Wu</surname><given-names>Y.C.</given-names></name>
<name><surname>Wu</surname><given-names>C.C.</given-names></name>
</person-group><article-title>Development of CpG-adjuvanted stable prefusion SARS-CoV-2 spike antigen as a subunit vaccine against COVID-19</article-title><source>Sci. Rep.</source><year>2020</year><volume>10</volume><elocation-id>20085</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-77077-z</pub-id><pub-id pub-id-type="pmid">33208827</pub-id>
</element-citation></ref><ref id="B97-vaccines-13-00193"><label>97.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Wang</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>S.</given-names></name>
<name><surname>Li</surname><given-names>B.</given-names></name>
<name><surname>Sun</surname><given-names>X.</given-names></name>
<name><surname>Pan</surname><given-names>Q.</given-names></name>
<name><surname>Zheng</surname><given-names>Y.</given-names></name>
<name><surname>Liu</surname><given-names>J.</given-names></name>
<name><surname>Zhao</surname><given-names>Y.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Liu</surname><given-names>L.</given-names></name>
<etal/>
</person-group><article-title>A novel CpG ODN compound adjuvant enhances immune response to spike subunit vaccines of porcine epidemic diarrhea virus</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1336239</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1336239</pub-id><pub-id pub-id-type="pmid">38322258</pub-id>
</element-citation></ref><ref id="B98-vaccines-13-00193"><label>98.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Koyama</surname><given-names>S.</given-names></name>
<name><surname>Aoshi</surname><given-names>T.</given-names></name>
<name><surname>Tanimoto</surname><given-names>T.</given-names></name>
<name><surname>Kumagai</surname><given-names>Y.</given-names></name>
<name><surname>Kobiyama</surname><given-names>K.</given-names></name>
<name><surname>Tougan</surname><given-names>T.</given-names></name>
<name><surname>Sakurai</surname><given-names>K.</given-names></name>
<name><surname>Coban</surname><given-names>C.</given-names></name>
<name><surname>Horii</surname><given-names>T.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<etal/>
</person-group><article-title>Plasmacytoid Dendritic Cells Delineate Immunogenicity of Influenza Vaccine Subtypes</article-title><source>Sci. Transl. Med.</source><year>2010</year><volume>2</volume><fpage>25ra24</fpage><pub-id pub-id-type="doi">10.1126/scitranslmed.3000759</pub-id></element-citation></ref><ref id="B99-vaccines-13-00193"><label>99.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Le</surname><given-names>C.T.T.</given-names></name>
<name><surname>Ahn</surname><given-names>S.Y.</given-names></name>
<name><surname>Ho</surname><given-names>T.L.</given-names></name>
<name><surname>Lee</surname><given-names>J.</given-names></name>
<name><surname>Lee</surname><given-names>D.H.</given-names></name>
<name><surname>Hwang</surname><given-names>H.S.</given-names></name>
<name><surname>Kang</surname><given-names>S.M.</given-names></name>
<name><surname>Ko</surname><given-names>E.J.</given-names></name>
</person-group><article-title>Adjuvant efects of combination monophosphoryl lipid A and poly I:C on antigen specifc immune responses and protective efcacy of infuenza vaccines</article-title><source>Sci. Rep.</source><year>2023</year><volume>13</volume><elocation-id>12231</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-023-39210-6</pub-id><pub-id pub-id-type="pmid">37507413</pub-id>
</element-citation></ref><ref id="B100-vaccines-13-00193"><label>100.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Gogoi</surname><given-names>H.</given-names></name>
<name><surname>Mansouri</surname><given-names>S.</given-names></name>
<name><surname>Jin</surname><given-names>L.</given-names></name>
</person-group><article-title>The Age of Cyclic Dinucleotide Vaccine Adjuvants</article-title><source>Vaccines</source><year>2020</year><volume>8</volume><elocation-id>453</elocation-id><pub-id pub-id-type="doi">10.3390/vaccines8030453</pub-id><pub-id pub-id-type="pmid">32823563</pub-id>
</element-citation></ref><ref id="B101-vaccines-13-00193"><label>101.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Sato</surname><given-names>Y.</given-names></name>
<name><surname>Roman</surname><given-names>M.</given-names></name>
<name><surname>Tighe</surname><given-names>H.</given-names></name>
<name><surname>Lee</surname><given-names>D.</given-names></name>
<name><surname>Corr</surname><given-names>M.</given-names></name>
<name><surname>Nguyen</surname><given-names>M.D.</given-names></name>
<name><surname>Silverman</surname><given-names>G.J.</given-names></name>
<name><surname>Lotz</surname><given-names>M.</given-names></name>
<name><surname>Carson</surname><given-names>D.A.</given-names></name>
<name><surname>Raz</surname><given-names>E.</given-names></name>
</person-group><article-title>Immunostimulatory DNA Sequences Necessary for Effective Intradermal Gene Immunization</article-title><source>Science</source><year>1996</year><volume>273</volume><fpage>352</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1126/science.273.5273.352</pub-id><pub-id pub-id-type="pmid">8662521</pub-id>
</element-citation></ref><ref id="B102-vaccines-13-00193"><label>102.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Takeuchi</surname><given-names>O.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
</person-group><article-title>Pattern recognition receptors and inflammation</article-title><source>Cell</source><year>2010</year><volume>140</volume><fpage>805</fpage><lpage>820</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2010.01.022</pub-id><pub-id pub-id-type="pmid">20303872</pub-id>
</element-citation></ref><ref id="B103-vaccines-13-00193"><label>103.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Suschak</surname><given-names>J.J.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Fitzgerald</surname><given-names>K.A.</given-names></name>
<name><surname>Lu</surname><given-names>S.</given-names></name>
</person-group><article-title>Identification of Aim2 as a Sensor for DNA Vaccines</article-title><source>J. Immunol.</source><year>2015</year><volume>194</volume><fpage>630</fpage><lpage>636</lpage><pub-id pub-id-type="doi">10.4049/jimmunol.1402530</pub-id><pub-id pub-id-type="pmid">25488991</pub-id>
</element-citation></ref><ref id="B104-vaccines-13-00193"><label>104.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ishii</surname><given-names>K.J.</given-names></name>
<name><surname>Kawagoe</surname><given-names>T.</given-names></name>
<name><surname>Koyama</surname><given-names>S.</given-names></name>
<name><surname>Matsui</surname><given-names>K.</given-names></name>
<name><surname>Kumar</surname><given-names>H.</given-names></name>
<name><surname>Kawai</surname><given-names>T.</given-names></name>
<name><surname>Uematsu</surname><given-names>S.</given-names></name>
<name><surname>Takeuchi</surname><given-names>O.</given-names></name>
<name><surname>Takeshita</surname><given-names>F.</given-names></name>
<name><surname>Coban</surname><given-names>C.</given-names></name>
<etal/>
</person-group><article-title>TANK-binding kinase-1 delineates innate and adaptive immune responses to DNA vaccines</article-title><source>Nature</source><year>2008</year><volume>451</volume><fpage>725</fpage><lpage>729</lpage><pub-id pub-id-type="doi">10.1038/nature06537</pub-id><pub-id pub-id-type="pmid">18256672</pub-id>
</element-citation></ref><ref id="B105-vaccines-13-00193"><label>105.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Li</surname><given-names>X.D.</given-names></name>
<name><surname>Wu</surname><given-names>J.</given-names></name>
<name><surname>Gao</surname><given-names>D.</given-names></name>
<name><surname>Wang</surname><given-names>H.</given-names></name>
<name><surname>Sun</surname><given-names>L.</given-names></name>
<name><surname>Chen</surname><given-names>Z.J.</given-names></name>
</person-group><article-title>Pivotal roles of cGAS-cGAMP signaling in antiviral defense and immune adjuvant effects</article-title><source>Science</source><year>2013</year><volume>341</volume><fpage>1390</fpage><lpage>1394</lpage><pub-id pub-id-type="doi">10.1126/science.1244040</pub-id><pub-id pub-id-type="pmid">23989956</pub-id>
</element-citation></ref><ref id="B106-vaccines-13-00193"><label>106.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>McWhirter</surname><given-names>S.M.</given-names></name>
<name><surname>Jefferies</surname><given-names>C.A.</given-names></name>
</person-group><article-title>Nucleic acid sensors as therapeutic targes for human disease</article-title><source>Immunity</source><year>2020</year><volume>52</volume><fpage>78</fpage><lpage>97</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2020.04.004</pub-id></element-citation></ref><ref id="B107-vaccines-13-00193"><label>107.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karik&#x000f3;</surname><given-names>K.</given-names></name>
<name><surname>Ni</surname><given-names>H.</given-names></name>
<name><surname>Capodici</surname><given-names>J.</given-names></name>
<name><surname>Lamphier</surname><given-names>M.</given-names></name>
<name><surname>Weissman</surname><given-names>D.</given-names></name>
</person-group><article-title>mRNA Is an Endogenous Ligand for Toll-like Receptor 3</article-title><source>J. Biol. Chem.</source><year>2004</year><volume>279</volume><fpage>12542</fpage><lpage>12550</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310175200</pub-id><pub-id pub-id-type="pmid">14729660</pub-id>
</element-citation></ref><ref id="B108-vaccines-13-00193"><label>108.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Tatematsu</surname><given-names>M.</given-names></name>
<name><surname>Funami</surname><given-names>K.</given-names></name>
<name><surname>Seya</surname><given-names>T.</given-names></name>
<name><surname>Matsumoto</surname><given-names>M.</given-names></name>
</person-group><article-title>Extracellular RNA Sensing by Pattern Recognition Receptors</article-title><source>J. Innate Immun.</source><year>2018</year><volume>10</volume><fpage>398</fpage><lpage>406</lpage><pub-id pub-id-type="doi">10.1159/000494034</pub-id><pub-id pub-id-type="pmid">30404092</pub-id>
</element-citation></ref><ref id="B109-vaccines-13-00193"><label>109.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Zhang</surname><given-names>C.</given-names></name>
<name><surname>Maruggi</surname><given-names>G.</given-names></name>
<name><surname>Shan</surname><given-names>H.</given-names></name>
<name><surname>Li</surname><given-names>J.</given-names></name>
</person-group><article-title>Advances in mRNA Vaccines for Infectious Diseases</article-title><source>Front. Immunol.</source><year>2019</year><volume>10</volume><elocation-id>594</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2019.00594</pub-id><pub-id pub-id-type="pmid">30972078</pub-id>
</element-citation></ref><ref id="B110-vaccines-13-00193"><label>110.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Goubau</surname><given-names>D.</given-names></name>
<name><surname>Schlee</surname><given-names>M.</given-names></name>
<name><surname>Deddouche</surname><given-names>S.</given-names></name>
<name><surname>Pruijssers</surname><given-names>A.J.</given-names></name>
<name><surname>Zillinger</surname><given-names>T.</given-names></name>
<name><surname>Goldeck</surname><given-names>M.</given-names></name>
<name><surname>Schuberth</surname><given-names>C.</given-names></name>
<name><surname>Van der Veen</surname><given-names>A.G.</given-names></name>
<name><surname>Fujimura</surname><given-names>T.</given-names></name>
<name><surname>Rehwinkel</surname><given-names>J.</given-names></name>
<etal/>
</person-group><article-title>Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5&#x02032;-diphosphates</article-title><source>Nature</source><year>2014</year><volume>514</volume><fpage>372</fpage><lpage>375</lpage><pub-id pub-id-type="doi">10.1038/nature13590</pub-id><pub-id pub-id-type="pmid">25119032</pub-id>
</element-citation></ref><ref id="B111-vaccines-13-00193"><label>111.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Luan</surname><given-names>X.</given-names></name>
<name><surname>Wang</surname><given-names>L.</given-names></name>
<name><surname>Song</surname><given-names>G.</given-names></name>
<name><surname>Zhou</surname><given-names>W.</given-names></name>
</person-group><article-title>Innate immune responses to RNA: Sensing and signaling</article-title><source>Front. Immunol.</source><year>2024</year><volume>15</volume><elocation-id>1287940</elocation-id><pub-id pub-id-type="doi">10.3389/fimmu.2024.1287940</pub-id><pub-id pub-id-type="pmid">38343534</pub-id>
</element-citation></ref><ref id="B112-vaccines-13-00193"><label>112.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Martin</surname><given-names>S.</given-names></name>
<name><surname>Hartmann</surname><given-names>G.</given-names></name>
</person-group><article-title>Discriminating self from non-self in nucleic acid sensing</article-title><source>Nat. Rev. Immunol.</source><year>2016</year><volume>16</volume><fpage>566</fpage><lpage>580</lpage><pub-id pub-id-type="doi">10.1038/nri.2016.78</pub-id><pub-id pub-id-type="pmid">27455396</pub-id>
</element-citation></ref><ref id="B113-vaccines-13-00193"><label>113.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Kim</surname><given-names>S.C.</given-names></name>
<name><surname>Sekhon</surname><given-names>S.S.</given-names></name>
<name><surname>Shin</surname><given-names>W.R.</given-names></name>
<name><surname>Ahn</surname><given-names>G.</given-names></name>
<name><surname>Cho</surname><given-names>B.K.</given-names></name>
<name><surname>Ahn</surname><given-names>J.Y.</given-names></name>
<name><surname>Kim</surname><given-names>Y.H.</given-names></name>
</person-group><article-title>Modifications of mRNA vaccine structural elements for improving mRNA stability and translation efficiency</article-title><source>Mol. Cell. Toxicol.</source><year>2022</year><volume>18</volume><fpage>1</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1007/s13273-021-00171-4</pub-id><pub-id pub-id-type="pmid">34567201</pub-id>
</element-citation></ref><ref id="B114-vaccines-13-00193"><label>114.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Costa-Mattioli</surname><given-names>M.</given-names></name>
<name><surname>Walter</surname><given-names>P.</given-names></name>
</person-group><article-title>The integrated stress response: From mechanism to disease</article-title><source>Science</source><year>2020</year><volume>368</volume><fpage>eaat5314</fpage><pub-id pub-id-type="doi">10.1126/science.aat5314</pub-id><pub-id pub-id-type="pmid">32327570</pub-id>
</element-citation></ref><ref id="B115-vaccines-13-00193"><label>115.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Karik&#x000f3;</surname><given-names>K.</given-names></name>
<name><surname>Buckstein</surname><given-names>M.</given-names></name>
<name><surname>Ni</surname><given-names>H.</given-names></name>
<name><surname>Weissman</surname><given-names>D.</given-names></name>
</person-group><article-title>Suppression of RNA Recognition by Toll-like Receptors: The Impact of Nucleoside Modification and the Evolutionary Origin of RNA</article-title><source>Immunity</source><year>2005</year><volume>23</volume><fpage>165</fpage><lpage>175</lpage><pub-id pub-id-type="doi">10.1016/j.immuni.2005.06.008</pub-id><pub-id pub-id-type="pmid">16111635</pub-id>
</element-citation></ref><ref id="B116-vaccines-13-00193"><label>116.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Liu</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>X.</given-names></name>
</person-group><article-title>The Pivotal Role of Chemical Modifications in mRNA Therapeutics</article-title><source>Front. Cell Dev. Biol.</source><year>2022</year><volume>10</volume><elocation-id>901510</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2022.901510</pub-id><pub-id pub-id-type="pmid">35912117</pub-id>
</element-citation></ref><ref id="B117-vaccines-13-00193"><label>117.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Hornung</surname><given-names>V.</given-names></name>
<name><surname>Ellegast</surname><given-names>J.</given-names></name>
<name><surname>Kim</surname><given-names>S.</given-names></name>
<name><surname>Brz&#x000f3;zka</surname><given-names>K.</given-names></name>
<name><surname>Jung</surname><given-names>A.</given-names></name>
<name><surname>Kato</surname><given-names>H.</given-names></name>
<name><surname>Poeck</surname><given-names>H.</given-names></name>
<name><surname>Akira</surname><given-names>S.</given-names></name>
<name><surname>Conzelmann</surname><given-names>K.K.</given-names></name>
<name><surname>Schlee</surname><given-names>M.</given-names></name>
<etal/>
</person-group><article-title>5&#x02019;-Triphosphate RNA Is the Ligand for RIG-I</article-title><source>Science</source><year>2006</year><volume>314</volume><fpage>994</fpage><lpage>997</lpage><pub-id pub-id-type="doi">10.1126/science.1132505</pub-id><pub-id pub-id-type="pmid">17038590</pub-id>
</element-citation></ref><ref id="B118-vaccines-13-00193"><label>118.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Anderson</surname><given-names>B.R.</given-names></name>
<name><surname>Muramatsu</surname><given-names>H.</given-names></name>
<name><surname>Nallagatla</surname><given-names>S.R.</given-names></name>
<name><surname>Bevilacqua</surname><given-names>P.C.</given-names></name>
<name><surname>Sansing</surname><given-names>L.H.</given-names></name>
<name><surname>Weissman</surname><given-names>D.</given-names></name>
<name><surname>Karik&#x000f3;</surname><given-names>K.</given-names></name>
</person-group><article-title>Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation</article-title><source>Nucleic Acids Res.</source><year>2010</year><volume>38</volume><fpage>5884</fpage><lpage>5892</lpage><pub-id pub-id-type="doi">10.1093/nar/gkq347</pub-id><pub-id pub-id-type="pmid">20457754</pub-id>
</element-citation></ref><ref id="B119-vaccines-13-00193"><label>119.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Lu</surname><given-names>T.</given-names></name>
<name><surname>Chen</surname><given-names>A.</given-names></name>
<name><surname>Wang</surname><given-names>S.</given-names></name>
<name><surname>Zhang</surname><given-names>Y.</given-names></name>
<name><surname>Yang</surname><given-names>B.</given-names></name>
<name><surname>Wang</surname><given-names>J.</given-names></name>
<name><surname>Fang</surname><given-names>H.</given-names></name>
<name><surname>Gong</surname><given-names>Q.</given-names></name>
<name><surname>Li</surname><given-names>A.</given-names></name>
<name><surname>Liu</surname><given-names>X.</given-names></name>
<etal/>
</person-group><article-title>N1-methylpseudouridine mRNA modification enhances efficiency and specificity of gene 1 overexpression by preventing Prkra-mediated global translation repression</article-title><source>BioRxiv</source><year>2024</year><pub-id pub-id-type="doi">10.1101/2024.12.06.627293</pub-id></element-citation></ref><ref id="B120-vaccines-13-00193"><label>120.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Despic</surname><given-names>V.</given-names></name>
<name><surname>Jaffrey</surname><given-names>S.R.</given-names></name>
</person-group><article-title>mRNA ageing shapes the Cap2 methylome in mammalian mRNA</article-title><source>Nature</source><year>2023</year><volume>614</volume><fpage>358</fpage><lpage>366</lpage><pub-id pub-id-type="doi">10.1038/s41586-022-05668-z</pub-id><pub-id pub-id-type="pmid">36725932</pub-id>
</element-citation></ref><ref id="B121-vaccines-13-00193"><label>121.</label><element-citation publication-type="journal"><person-group person-group-type="author">
<name><surname>Ramanathan</surname><given-names>A.</given-names></name>
<name><surname>Robb</surname><given-names>G.B.</given-names></name>
<name><surname>Chan</surname><given-names>S.H.</given-names></name>
</person-group><article-title>mRNA capping: Biological functions and applications</article-title><source>Nucleic Acids Res.</source><year>2016</year><volume>44</volume><fpage>7511</fpage><lpage>7526</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw551</pub-id><pub-id pub-id-type="pmid">27317694</pub-id>
</element-citation></ref></ref-list></back><floats-group><fig position="float" id="vaccines-13-00193-f001"><label>Figure 1</label><caption><p>Key roles of pattern recognition receptors in viral defense and vaccine-induced immunity. The innate immune system utilizes PRRs to detect PAMPs and initiate rapid immune responses. As an example, PRR activation triggers IFN-I production, which through IFNAR signaling induces antiviral gene expression, enhancing viral defense and vaccine efficacy. Created in BioRender. ENYA, T. (2025) Accessed on 9 December 2024. <uri xlink:href="https://BioRender.com/r45j084">https://BioRender.com/r45j084</uri>.</p></caption><graphic xlink:href="vaccines-13-00193-g001" position="float"/></fig><fig position="float" id="vaccines-13-00193-f002"><label>Figure 2</label><caption><p>Mechanisms of innate immunity triggered by mRNA vaccine. mRNA vaccine activates innate immunity via TLRs (TLR3, 7, 8) and RLRs (RIG-I, MDA5), inducing IFN-I production through IRF3 and NF&#x003ba;B signaling. Created in BioRender. ENYA, T. (2025). Accessed on 9 December 2024. <uri xlink:href="https://BioRender.com/p79c529">https://BioRender.com/p79c529</uri>.</p></caption><graphic xlink:href="vaccines-13-00193-g002" position="float"/></fig></floats-group></article>